NEEDLE TIPS
& the Hepatitis B Coalition News
Published by the Immunization Action Coalition for individuals and organizations concerned about vaccine-preventable diseases.

WHAT'S ON THE INSIDE:

Ask the Experts
CDC's William Atkinson, MD, answers immunization questions ............................................ 1
CDC's Harold Margolis, MD, and Linda Moyer, RN, answer hepatitis questions .................. 20

What's New?
Surgeon General’s Warning: 45,000 adults die yearly from vaccine-preventable diseases .... 2
“Today’s Vaccine Paradox” by Samuel L. Katz, MD, Vaccine Initiative ................................. 3
Vaccine Highlights: new vaccines and new recommendations .............................................. 4
“Hepatitis B Vaccine Is Safe” by Neal Halsey, MD, Institute for Vaccine Safety ............... 6
U.S. Congressman Joe Moakley encourages states to pass hepatitis B laws .................... 7
“Unprotected People” – two deaths ignite pneumococcal vaccine campaign ..................... 8

Photocopy these materials!
Revised! Summary of recommendations for childhood immunization .............................. 9
NEW! Rotavirus Vaccine Information Statement (VIS) .................................................. 11
NEW! “What would happen if we stopped vaccinating?” by CDC ................................. 13
NEW! “If you have sex, read this...” by Lynda Liu (reprinted from Mademoiselle) ........ 16

National Resources
Where to get immunization and hepatitis B reference books, videos, and more .............. 22

Coalition Catalog
Immunization and hepatitis B videos, brochures, etc. Order one, make copies! .............. 24

Join the Coalition!
A $50 annual membership will help support the Coalition plus we’ll send you a huge packet of all our printed materials, too! .................................................. 28

Ask the Experts
Editors' note: The Immunization Action Coalition thanks William L. Atkinson, MD, MPH, Harold S. Margolis, MD, and Linda A. Moyer, RN, of the Centers for Disease Control and Prevention for answering the following questions for our readers. Dr. Atkinson, medical epidemiologist at the National Immunization Program, and Dr. Margolis, chief of the Hepatitis Branch, serve as CDC liaisons to the Coalition. Ms. Moyer is an epidemiologist at the Hepatitis Branch.

General vaccine questions
by William L. Atkinson, MD, MPH

Why do ACIP recommendations not always agree with package inserts?
There is usually very close agreement between vaccine package inserts and ACIP statements. The Food and Drug Administration must approve the package insert, and requires documentation for all claims and recommendations made in the insert. Occasionally, ACIP may use different data to formulate its recommendations, or try to add flexibility to its recommendations, which results in wording different than on the insert.

If my state has a registry, do I still need to give patients vaccine record cards?
Yes. Patient-held cards are an extremely important part of a person’s medical history. The person may move to an area without a registry, and the personal record may be the only vaccination record available. In addition, even within a state, all health care providers may not participate in the registry, and the personal record card would be needed.

An 11-year old with no immunization record recently immigrated to the USA. What do I do?
An attempt should be made to locate an immunization record. If no record can be located, the person should be revaccinated as indicated for his or her age. You should never assume that anyone was vaccinated without documentation. The child will need the following vaccines: Td, IPV, hepatitis B, MMR, and varicella (or a reliable history of the disease).

What vaccines should be given to adults who have had bone marrow transplants?
ACIP is currently formulating recommendations for the vaccination of persons receiving bone marrow and other hematopoietic cell transplants. While

(continued on page 17)

Immunization questions?
• E-mail nipinfo@cdc.gov
• Call your state health department (phone numbers on page 23)
• Call CDC's Immunization Information Hotline at 800/232-2522

Sign up for IAC EXPRESS!
To subscribe, send an e-mail request to express@immunize.org and place the word SUBSCRIBE in the "Subject:" field. You will receive timely immunization and hepatitis news from us via e-mail.
To All Immunization Action Coalition Members:

While childhood immunization rates in the U.S. are at an all-time high—with the most critical vaccine doses reflecting coverage rates of over 90 percent—the news is not as good among older adults, who are at increased risk for many vaccine-preventable diseases. Each year an estimated 45,000 adults die of infections related to influenza, pneumococcal disease, and hepatitis B despite the availability of safe and effective vaccines to prevent these conditions and their complications.

Approximately 90 percent of all influenza-associated deaths in the United States occur in people aged 65 and older, the fastest growing age group of the population. Reduction of deaths in this age group has been hindered in part by relatively low vaccine utilization.

There is a disproportionate burden of these diseases in minority and underserved populations. Although vaccination levels against pneumococcal infections and influenza among people 65 years and older have increased slightly for Blacks and Hispanics, the coverage in both these groups remains substantially below the overall population.

People aged 65 and older who reported receiving vaccines (by race/ethnicity)

Influenza vaccine
- White, non-Hispanic .................... 67.2%
- Black, non-Hispanic ..................... 50.2%
- Hispanic .................................. 57.9%

Pneumococcal vaccine
- White, non-Hispanic .................... 47.3%
- Black, non-Hispanic ..................... 29.7%
- Hispanic .................................. 34.1%


The reduction in incidence of vaccine-preventable diseases is one of the most significant public health achievements of the past 100 years.

Immunization is one of the most cost-effective strategies to prevent needless morbidity and mortality. In addition, the overall cost to society for vaccine-preventable diseases exceeds $10 billion each year.

With your help and your dedication, we can continue to build upon the impressive health achievements that vaccines already have made possible. Thank you for your efforts.

David Satcher, MD, PhD
Assistant Secretary for Health
and U.S. Surgeon General
Our very success with infant and childhood vaccines during the past 40 years has paradoxically proven to be one of our major liabilities in maintaining high levels of immunization for today’s infants and children.

In the 1950s, parents and grandparents were personally familiar with the annual summer–autumn devastations of polio with 25,000 or more victims ending up with braces, crutches, wheelchairs, or in iron lungs. Similarly, the vision of a child choking and strangling from obstruction to breathing caused by pneumonia of the lungs. Similarly, the vision of a child choking and strangling from obstruction to breathing caused by diphtheria was well recognized by families in that same era.

More recently the millions of cases of measles that occurred every year have become increasingly rare. The pneumonia, diarrhea, and ear infections which complicated large numbers of measles patients were even less frightening than the encephalitis which claimed a smaller number, perhaps 1 in 1,000. Those who survived were left with deficits ranging from severe mental retardation to paralysis and seizures.

In one year in the 1960s, more than 25,000 infants were born with major malformations including deafness, blindness, congenital heart disease, and mental retardation due to rubella virus infecting their pregnant mothers. Once again a disorder of that magnitude has nearly disappeared thanks to effective rubella virus vaccines.

Today’s young parents have rarely if ever seen the toll of these diseases because of the success of our vaccine programs that prevent them.

More recently parents may have been aware of meningitis, most frequent in the first 18 months of life due to an organism called Haemophilus influenzae type b. Development and widespread use of vaccines to prevent this invasive infection have reduced the 20,000 cases of meningitis, epiglottitis and pneumonia with empyema that occurred each year to only a few hundred. Even today’s young physicians are unfamiliar with many of these diseases which formerly crowded the wards of our children’s hospitals.

These organisms have not disappeared but have only receded into the background.

These organisms have not disappeared but have only receded into the background due to the remarkable effects of vaccines developed to prevent them. Failure to continue these vaccine programs can have disastrous results as we saw in 1989 and 1990 when populations of inner-city children, who had not received measles vaccine, suffered a virulent outbreak of more than 50,000 cases which included all the complications of the past plus 125 deaths.

Some parents have been loath to have their children immunized because of unfortunate, misleading, exaggerated misinformation.

Regrettably, some parents have been loath to have their children immunized because of unfortunate, misleading, exaggerated misinformation regarding the rare, possible reactions to the vaccines. Biomedical scientists, pharmaceutical companies and the Food & Drug Administration continue to collaborate in their constant efforts to produce vaccines that are both safe and effective.

Why do we go to bed?

Because the bed won’t come to us!

Advisory Board

William L. Atkinson, MD, MPH
Liaison, National Immunization Program, CDC
Virginia Burggraf, MSN, RN
American Nurses Association, Washington, DC
Arthur Chen, MD
Alameda Co. Health Department, Oakland, CA
Moon S. Chen, Jr., PhD, MPH
Ohio State University
Richard D. Clover, MD
University of Louisville
Deborah K. Freese, MD
Mayo Clinic, Rochester, MN
Stanley A. Gall, MD
University of Louisville
Pierce Gardner, MD
State University of New York, Stony Brook
Bernard Gonik, MD
Wayne State University
John D. Grabenstein, MS Pharm, EdM
ImmunoFacts, Durham, NC
Caroline Breese Hall, MD
University of Rochester
Neal A. Halsey, MD
Johns Hopkins University
Hie-Won L. Hann, MD
Jefferson Medical College
Neal Holtan, MD, MPH
St. Paul Ramsey Co. Public Health, St. Paul, MN
Margaret K. Hostetter, MD
Yale University
Robert M. Jacobson, MD
Mayo Clinic, Rochester, MN
Jerri A. Jenista, MD
Adoption Medical News, Ann Arbor, MI
Samuel L. Katz, MD
Duke University Medical Center
Anne Knett, PIN
St. Paul Ramsey Co. Public Health, St. Paul, MN
B U.K. Li, MD
Ohio State University
Anna S.-F. Lok, MD
University of Michigan
Virginia R. Lupo, MD
Hennepin Co. Medical Center, Mpls., MN
Edgar K. Marcuse, MD, MPH
University of Washington School of Medicine
Harold S. Margolis, MD
Liaison, Hepatitis Branch, CDC
Christine C. Matson, MD
Eastern Virginia Medical School
James McCord, MD
Children’s Health Care – St. Paul, MN
Brian J. McMahon, MD
Alaska Native Medical Center, Anchorage, AK
Margaret Morrison, MD
Mississippi Department of Health
Paul A. Offit, MD
Children’s Hospital of Philadelphia
Gregory A. Poland, MD
Mayo Clinic, Rochester, MN
Gary Remafedi, MD, MPH
University of Minnesota
Thomas N. Saari, MD
University of Wisconsin
William Schaffner, MD
Vanderbilt University
Neil R. Schram, MD
Kaiser Permanente, Harbor City, CA
Sarah Jane Schwarzenberg, MD
University of Minnesota
Coleman I. Smith, MD
Minnesota Gastroenterology, Minneapolis, MN
Raymond A. Strikas, MD
Liaison, National Immunization Program, CDC
Myron J. Tong, PhD, MD
Huntington Memorial Hosp., Pasadena, CA
Walter W. Williams, MD
Liaison, Assoc. Director for Minority Health, CDC
Richard K. Zimmerman, MD, MPH
University of Pittsburgh
Deborah L. Wexler, MD
Executive Director

Needle Tips • Spring/Summer 1999 (printed 3/99) • 1573 Selby Avenue, St. Paul, MN 55104 • 651/647-9009 • www.immunize.org
Vaccine highlights
Latest recommendations and schedules

The next ACIP meetings...

Editors’ note: The information on this page is current as of March 8, 1999.

The Advisory Committee on Immunization Practices (ACIP) is a committee of 10 national experts that provides advice and guidance to CDC regarding the most appropriate use of vaccines and immune globulins. ACIP meetings are held three times a year in Atlanta, GA, and are open to the public. The next meetings will be held on June 16–17, 1999, and Oct. 20–21, 1999.

ACIP statement information

ACIP statements. No clinic should be without a set of these public health recommendations on vaccines which are published in the MMWR. Continuing education credits (CMEs, CEUs, CNEs) are available for reading and completing the brief tests found in the 1999 ACIP statements.

To get a complete set of ACIP statements or just the ones you want:
• Download individual statements from CDC’s website: www.cdc.gov/epo/mmwr/mmwr.html (You also can request a free electronic subscription to MMWR at this site.)
• E-mail your request to nipinfo@cdc.gov
• Call CDC’s Immunization Information Hotline: 800-232-2522.
• Call your state’s immunization program (phone numbers on page 23).
• Request them from your medical library.
• Call 781-893-3800 to subscribe to the MMWR.

The most recently published ACIP statements are as follows:
• Human Rabies Prevention – U.S. (1/8/99)
• Measles, Mumps, and Rubella – Vaccine Use and Strategies for Elimination of Measles, Rubella, and Congenital Rubella Syndrome and Control of Mumps (5/22/98)
• Prevention and Control of Influenza (5/1/98)

Varicella news and laws

On Feb. 17–18, 1999, the ACIP voted to recommend that “all states implement a requirement that children entering child care facilities and elementary school have received varicella vaccine or have other evidence of immunity to varicella.”

The following states have passed varicella vaccine school entry laws: Maryland, Massachusetts, Michigan, Oklahoma, Oregon, Rhode Island, and Virginia. The District of Columbia and San Antonio County, TX, have also passed varicella school entry laws.

On Feb. 17–18, 1999, the ACIP voted to expand the varicella vaccine recommendations to include information about: 1) postexposure use of varicella vaccine (see “Ask the Experts,” page 18); 2) varicella vaccine use for outbreak control; 3) vaccination of persons ≥13 years of age who are at high risk of exposure; and 4) considering the vaccine for a subset of HIV-positive children in CDC Class I with CD4% ≥25%. These recommendations will be published as a “Notice to Readers” in the MMWR (date unknown at the time of this writing).

Editors’ note: Varicella vaccine is recommended for all susceptible children 1 through 18 years of age. VFC vaccine can be used for any VFC-eligible child within this age range.

Rotavirus vaccine news

On Oct. 22, 1998, the ACIP voted to approve the inclusion of rotavirus vaccine in the Vaccines for Children program (VFC). Rotavirus vaccine will be available for distribution through VFC after a supply contract is finalized.

Rotavirus vaccine, an oral vaccine, is recommended for infants at 2, 4, and 6 months of age by the ACIP, the AAP, and the AAFP. These three groups recognize that the incorporation of this vaccine into clinical practice may require additional time and resources from health care providers. See “Ask the Experts,” page 18 for more information on the use of this vaccine.

Hepatitis A news

On Feb. 18, 1999, the ACIP voted to expand its hepatitis A vaccine recommendations to include children living in states, counties, and/or communities with hepatitis A rates consistently higher than the national average.

• Routine vaccination of children is recommended in states where the average annual hepatitis A rate during 1987–97 was at least 10/100,000 population but less than 20/100,000. These states are Arkansas, Colorado, Missouri, Montana, Texas, and Wyoming.

• Routine hepatitis A vaccination of children may also be considered in counties and/or communities where the average annual hepatitis A rate during 1987–97 was at least 10/100,000 population but less than 20/100,000.

Hepatitis B vaccine news

On Jan. 22, 1999, “Update: Recommendations to Prevent Hepatitis B Transmission—U.S.” was published as a “Notice to Readers” in the MMWR. It begins: “In Oct. 1997, the Advisory Committee on Immunization Practices expanded its hepatitis B vaccination recommendations to include all unvaccinated children aged 0–18 years and made hepatitis B vaccine available through the Vaccines for Children program (VFC) for persons aged 0–18 years who are eligible for VFC. ACIP pri-(continued on page 5)
in populations at high risk for hepatitis B virus (HBV) infection (e.g., Alaska Natives, Pacific Islanders, and children who reside in households of first-generation immigrants from countries where HBV infection is moderately or highly endemic); previously unvaccinated children aged 11–12 years; and older adolescents and adults in defined risk groups.”

On Jan. 22, 1999, the Vaccine Initiative issued a press release to clarify a statement by the National Vaccine Information Center (formerly known as Dissatisfied Parents Together [DPT]) that incorrectly portrayed the risks of serious side effects associated with giving the hepatitis B vaccine to children.

The Vaccine Initiative stated that “a published review of VAERS data from 1991–94 shows no unexpected events in infants who received approximately 12 million doses of the hepatitis B vaccine during that period. In addition, an analysis of data from the National Center for Health Statistics shows no increase in reports of infant deaths since 1991, the year routine hepatitis B immunization began.”

Editors’ note: The Vaccine Initiative, a special project of the Infectious Diseases Society of America and the Pediatric Infectious Diseases Society, is supported by a grant from the Robert Wood Johnson Foundation and is an independent source of information on immunization and immunization-related issues for parents, health professionals, legislators, and the media. Visit their website at www.idsociety.org or you can call 615-343-6306.

**Polio vaccine news**

On Oct. 21, 1998, the ACIP voted to no longer recommend OPV for the first two doses of the polio series, except in special circumstances such as a child whose parents do not accept the recommended number of injections, or an unvaccinated child who will be traveling within 4 weeks to a polio-endemic area.

**DTaP news**

In the 1999 Childhood Immunization Schedule the following statement appears: “DTaP is the preferred vaccine for all doses in the immunization series including completion of the series in children who have received one or more doses of whole-cell DTP vaccine.” DTP remains an acceptable alternative when DTaP is not available.

On Jan. 26, 1999, Pasteur-Mérieux Connaught, USA (PMC) issued a voluntary recall of Tripedia DTaP vaccine, lot #0916490, which was distributed between February and June 1998. Routine stability testing determined that the potency of the diphtheria component, which had been acceptable at the time of release, had fallen below specifications. Children traveling outside the U.S. who were vaccinated with Tripedia DTaP lot #0916490 may need supplemental doses of diphtheria toxoid-containing vaccines. Call CDC’s Immunization Hotline at 800-232-2522 for more information. Questions can also be addressed to PMC’s medical affairs department at 800-325-7709.

**Lyme disease vaccine news**

On Feb. 18, 1999, the ACIP voted to approve “Prevention of Lyme Disease through Active Vaccination,” the ACIP statement on Lyme disease. The statement will include ACIP recommendations on whom to vaccinate. The expected publication date is spring or summer 1999.

On Dec. 21, 1998, the FDA licensed LYMErix, a new Lyme disease vaccine manufactured by SmithKline Beecham. The vaccine is licensed for use in persons ages 15–70 years. It is given IM on a 0-, 1-, 12-month schedule.

**Rabies news**


**1999 Childhood IZ schedule**

On Jan. 15, 1999, the 1999 Childhood Immunization Schedule was published as a “Notice to Readers” in the MMWR. The new schedule has significant changes and new vaccine recommendations that were not on the 1998 schedule so make sure you have a copy. Call your state health department (phone numbers on page 23) or obtain it from CDC’s website: www.cdc.gov/nip/ and click on “Publications.” You can also call CDC’s Immunization Hotline at 800-232-2522.

**VISs (vax info statements)**

On Feb. 23, 1999, CDC published “Instructions for Use of Vaccine Information Materials (Vaccine Information Statements).” In these instructions CDC states that all health care providers in the U.S. who administer any vaccine containing diphtheria, tetanus, pertussis, measles, mumps, rubella, polio, hepatitis B, Haemophilus influenzae type b (Hib), or varicella (chickenpox) vaccine shall, prior to administration of each dose of the vaccine, provide a copy of the relevant vaccine information materials (also known as VISs) to the patient or parent/guardian.

In Feb. 1999, CDC released five new Vaccine Information Statements (VISs) – varicella, MMR, Hib, hepatitis B, and polio.

You must give your patients the most current versions of the VISs (the date appears at the bottom of each VIS). Note: VISs dated Dec. 16, 1998, must be in place no later than June 1, 1999, and the interim polio vaccine information materials, dated Feb. 1, 1999, must be used as soon as practicable. Following is a table of the most current VISs and the date that is at the bottom of each one. Use the current ones and throw away (recycle) your old ones.

**Current VISs**

<table>
<thead>
<tr>
<th>DTaP/DTP</th>
<th>Hib</th>
<th>MMR</th>
<th>Hib</th>
<th>polio</th>
<th>varicella</th>
<th>Td</th>
<th>polio</th>
<th>Hib</th>
<th>hepatitis B</th>
<th>pneumococcal</th>
<th>influenza</th>
</tr>
</thead>
<tbody>
<tr>
<td>8/15/97</td>
<td>12/16/98</td>
<td>12/16/98</td>
<td>2/1/99</td>
<td>12/16/98</td>
<td>8/25/98</td>
<td>7/29/97</td>
<td>7/1/98</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

In January, CDC released a rotavirus interim VIS, which is reprinted on pages 11–12 of this issue of NEEDLE TIPS. The rotavirus VIS, dated Dec. 1, 1998, is not required at this time but is an excellent information piece for parents.

VISs and the instructions on how to use them can be obtained from your state health department (phone numbers on page 23). The VISs and the new VIS instruction sheet are also on IAC’s website at: www.immunize.org/vis/

**VFC coverage in 1999**

As of March 1, 1999, the age guidelines (for children who are VFC-eligible) are as follows:

- Children 1 through 18 years of age are eligible to receive two doses of MMR vaccine and one or two doses of varicella vaccine (depending on the child’s age at the time of vaccination).
- Children 0 through 18 years of age are eligible to receive three doses of hepatitis B vaccine.
- Children 11 through 18 years of age are eligible to receive a Td vaccine booster if at least 5 years have elapsed since the previous dose.
- Children 0 through 18 years of age who need routine or catch-up doses are eligible to receive DTaP, DT, Td, polio, and Hib vaccines.
- Children 2 through 18 years of age are eligible for pneumococcal vaccine if they are in an ACIP-recommended risk group.

**NOTE:** Some states have used state funding to expand these age limits. Check with your state immunization program (phone numbers on page 23).
Hepatitis B vaccines are safe and effective

This article was written by Neal A. Halsey, MD, Director, Institute for Vaccine Safety, Johns Hopkins School of Public Health, in response to recent news reports about hepatitis B vaccine, multiple sclerosis, and other disorders.

Hepatitis B vaccines provide protection against serious and life-threatening liver diseases including cancer of the liver. More than 20 million persons in the U.S. and more than 500 million worldwide have been immunized. However, recent news reports have questioned the safety of hepatitis B vaccines and suggested associations between the vaccine and multiple sclerosis (MS) and other autoimmune disorders. Unfortunately, these news reports have not included the results of expert panels who have carefully reviewed the data and found no scientific evidence of a causal relationship between hepatitis B vaccine and MS and other disorders.

Media stories have focused on anecdotal reports of adults and children who developed disorders after vaccination. Because the disorders developed at varying times after hepatitis B vaccination, some people (falsely) concluded that the disorders might have been caused by hepatitis B vaccines.

Hepatitis B vaccines should be given to all children as part of their routine vaccination schedule

Hepatitis B infection is not a risk factor for developing MS and there has been no increase in MS or other disorders associated with the introduction of hepatitis B vaccine and MS and other disorders.

For more information on vaccine safety, visit the Vaccine Safety Resources listed below.

On September 28–30, 1998, the Viral Hepatitis Prevention Board (VHPB) assembled experts to review the epidemiology and current understanding of MS. The panel of experts concluded that available data do not demonstrate a causal association between hepatitis B immunization and demyelinating disorders including MS. [Halsey NA, Duclos P, Van Damme P, Margolis H. Hepatitis B vaccine and central nervous system demyelinating diseases. Pediatric Infectious Disease Journal 1999;18:23-24.]

Editors’ note: To obtain the VHPB’s summary statement on the hepatitis B vaccine and MS from the Internet, visit: http://esoc-www.uia.ac.be/esoc/VHPB/statement.html

Prior to routine immunization, every year in the U.S. more than 300,000 people developed hepatitis B infections and 5,000 died from chronic hepatitis or cancer of the liver caused by chronic hepatitis B infection. Hepatitis B vaccines provide 95% protection against chronic hepatitis B infection. Therefore, the World Health Organization, the American Academy of Pediatrics, the American Academy of Family Physicians, and the Advisory Committee on Immunization Practices of the CDC all recommend that all children 0–18 years of age should receive the vaccine.

Parents should not be misled by the occasional inflammatory reports in the press. Hepatitis B vaccines are very safe and effective and should continue to be given to all children as part of their routine vaccination schedule.

On March 20, 1998, the Institute for Vaccine Safety convened a panel of experts to review data regarding the relationship between Type 1 diabetes and immunization. The panel concluded that vaccines are not responsible for causing diabetes and that some vaccines might prevent diabetes. In animals predisposed to developing diabetes, some vaccines administered early in life prevent diabetes. Several studies are underway to determine if hepatitis B vaccine at birth is associated with a reduced risk of diabetes in high-risk children. [The Institute for Vaccine Safety Diabetes Workshop Panel. Childhood Immunizations and Type 1 Diabetes: Summary of an Institute for Safety Workshop. Pediatric Infectious Disease Journal 1999;18:217-22.]

Vaccine Safety Resources

- National Immunization Program: www.cdc.gov/nip/vacsafe/
- CDC’s Hepatitis Branch: www.cdc.gov/nccdod/diseases/hepatitis/index.htm
- CDC Immunization Hotline: 800-232-2522
- Institute for Vaccine Safety: 410-955-2955 www.vaccinesafety.edu
- Immunization Action Coalition: 651-647-9009 www.immunize.org
- IAC EXPRESS: www.immunize.org/express/
**What’s your state doing?**

**U.S. Congressman encourages states to pass laws that will help protect schoolchildren from hepatitis B**

The Immunization Action Coalition received the following letter from U.S. Congressman John Joseph Moakley, House of Representatives, 9th District, Massachusetts. In his letter, Congressman Moakley describes his personal battle with hepatitis B and writes about his successful liver transplant. In his letter, he also encourages states to add hepatitis B vaccine to their school immunization laws, rules, or regulations.

### Don’t Hesitate, Vaccinate!

In the early 1980s, I was diagnosed with hepatitis B. It has never been determined where or how I contracted the virus. It may have been during a Congressional fact finding trip to China at that time. That is one of the very frightening facts about hepatitis B. While risk factors have been identified that are associated with viral transmission, up to 40 percent of the cases of hepatitis B in adults have no known risk factors associated with them.

By 1995, I was told by my doctors that I had about two months to live. In my case, the hepatitis B virus had led to cirrhosis of the liver and this vital organ had deteriorated beyond function. I was terribly ill. I had no strength and I had become severely jaundiced. But I was lucky; a liver transplant saved my life.

Today, I am happy, healthy and so grateful that I have been able to celebrate 25 years in the United States Congress.

Unfortunately, more than one and a quarter million Americans have hepatitis B, and up to 6,000 Americans every year die from the complications associated with the hepatitis B virus. All of the horrors that I endured could have been avoided if I had had available to me the very safe and effective vaccine against hepatitis B that now exists. The three shot series over a period of four to six months can protect most people from the agony of this disease.

I strongly encourage states to add hepatitis B vaccine to their school immunization laws, rules, or regulations. I also urge everyone to check with their providers about immunization against hepatitis B for themselves and for those they love.

There is no reason for anyone to suffer from this totally preventable disease.

Sincerely,

Joe Moakley

Member of Congress

**Editors’ note:** Since 1996, thanks to a statewide hepatitis B school mandate, Massachusetts children in daycare, kindergarten and first grade have been protected from hepatitis B virus infection. Starting in the fall of 1999, middle school students in Massachusetts were required to have hepatitis B vaccination.

To date, 41 states plus the District of Columbia have added hepatitis B vaccination to their list of vaccinations that are required for school.

### Needle Tips

- Spring/Summer 1998 (printed 3/99)
- 1573 Selby Avenue, St. Paul, MN 55104
- 651/647-9009
- www.immunize.org

---

### Table: Hepatitis B Mandates in States

<table>
<thead>
<tr>
<th>State</th>
<th>Do you have any hepatitis B childhood vaccination mandate?</th>
<th>Is there a hepatitis B daycare law? Who is covered &amp;/or what is date of implementation?</th>
<th>Is there a hepatitis B kindergarten &amp;/or 1st grade law? Date of implementation?</th>
<th>Is there a hepatitis B middle school law? Date of implementation?</th>
</tr>
</thead>
<tbody>
<tr>
<td>AL</td>
<td>yes</td>
<td>yes 9/97</td>
<td>yes 9/97</td>
<td></td>
</tr>
<tr>
<td>AK</td>
<td>yes</td>
<td>yes 9/97</td>
<td>yes 9/97</td>
<td></td>
</tr>
<tr>
<td>AZ</td>
<td>yes</td>
<td>yes 97</td>
<td>yes 97</td>
<td></td>
</tr>
<tr>
<td>AR</td>
<td>yes</td>
<td>yes 97</td>
<td>yes 98</td>
<td>yes 9/99</td>
</tr>
<tr>
<td>CA</td>
<td>yes</td>
<td>yes 97</td>
<td>yes 97</td>
<td>yes 9/99</td>
</tr>
<tr>
<td>CO</td>
<td>yes</td>
<td>yes 97</td>
<td>yes 97</td>
<td></td>
</tr>
<tr>
<td>CT</td>
<td>yes</td>
<td>yes 95</td>
<td>yes 96</td>
<td></td>
</tr>
<tr>
<td>DE</td>
<td>yes</td>
<td>yes 90/99</td>
<td>yes 90/99</td>
<td></td>
</tr>
<tr>
<td>DC</td>
<td>yes</td>
<td>yes 97</td>
<td>yes 97</td>
<td></td>
</tr>
<tr>
<td>FL</td>
<td>yes</td>
<td>yes 98</td>
<td>yes 98</td>
<td></td>
</tr>
<tr>
<td>GA</td>
<td>yes</td>
<td>yes 97</td>
<td>yes 97</td>
<td></td>
</tr>
<tr>
<td>HI</td>
<td>yes</td>
<td>yes 98</td>
<td>yes 98</td>
<td></td>
</tr>
<tr>
<td>ID</td>
<td>yes</td>
<td>born after 11/91</td>
<td>born after 11/91</td>
<td>born after 11/91</td>
</tr>
<tr>
<td>IL</td>
<td>yes</td>
<td>yes 98</td>
<td>yes 98</td>
<td></td>
</tr>
<tr>
<td>IN</td>
<td>yes</td>
<td>yes 7/99</td>
<td>yes 7/99</td>
<td></td>
</tr>
<tr>
<td>IA</td>
<td>yes</td>
<td>yes 1/99</td>
<td>yes 1/99</td>
<td></td>
</tr>
<tr>
<td>KS</td>
<td>yes</td>
<td>yes 9/99</td>
<td>yes 9/99</td>
<td></td>
</tr>
<tr>
<td>KY</td>
<td>yes</td>
<td>yes 98</td>
<td>yes 98</td>
<td></td>
</tr>
<tr>
<td>LA</td>
<td>yes</td>
<td>yes 98</td>
<td>yes 98</td>
<td></td>
</tr>
<tr>
<td>ME</td>
<td>yes</td>
<td>yes 95</td>
<td>yes 95</td>
<td>yes 9/01</td>
</tr>
<tr>
<td>MA</td>
<td>yes</td>
<td>yes 96</td>
<td>yes 96</td>
<td>yes 9/99</td>
</tr>
<tr>
<td>MI</td>
<td>yes</td>
<td>yes 97</td>
<td>yes 1/00</td>
<td></td>
</tr>
<tr>
<td>MN</td>
<td>yes</td>
<td>yes 90/99</td>
<td>yes 90/99</td>
<td>yes 9/01</td>
</tr>
<tr>
<td>MS</td>
<td>yes</td>
<td>yes 8/99</td>
<td>yes 8/99</td>
<td></td>
</tr>
<tr>
<td>MO</td>
<td>yes</td>
<td>yes 95</td>
<td>yes 96</td>
<td></td>
</tr>
<tr>
<td>MT</td>
<td>yes</td>
<td>yes 9/99</td>
<td>yes 7/99</td>
<td>yes 7/00</td>
</tr>
<tr>
<td>NE</td>
<td>yes</td>
<td>yes 96</td>
<td>yes 96</td>
<td></td>
</tr>
<tr>
<td>NH</td>
<td>yes</td>
<td>yes 96</td>
<td>yes 96</td>
<td></td>
</tr>
<tr>
<td>NJ</td>
<td>yes</td>
<td>yes 96</td>
<td>yes 96</td>
<td></td>
</tr>
<tr>
<td>NM</td>
<td>yes</td>
<td>yes 9/00</td>
<td>yes 9/02</td>
<td>yes 9/99</td>
</tr>
<tr>
<td>NY</td>
<td>yes</td>
<td>yes 95</td>
<td>yes 98</td>
<td></td>
</tr>
<tr>
<td>NC</td>
<td>yes</td>
<td>born after 7/94</td>
<td>born after 7/94</td>
<td>born after 7/94</td>
</tr>
<tr>
<td>ND</td>
<td>yes</td>
<td>yes 98</td>
<td>yes 98</td>
<td></td>
</tr>
<tr>
<td>OH</td>
<td>yes</td>
<td>yes 8/99</td>
<td>yes 8/99</td>
<td></td>
</tr>
<tr>
<td>OK</td>
<td>yes</td>
<td>yes 97</td>
<td>yes 97</td>
<td></td>
</tr>
<tr>
<td>OR</td>
<td>yes</td>
<td>yes 98</td>
<td>yes 98</td>
<td>yes 9/00</td>
</tr>
<tr>
<td>PA</td>
<td>yes</td>
<td>yes 97</td>
<td>yes 97</td>
<td></td>
</tr>
<tr>
<td>RI</td>
<td>yes</td>
<td>yes 8/99</td>
<td>yes 8/99</td>
<td>yes 8/00</td>
</tr>
<tr>
<td>SC</td>
<td>yes</td>
<td>yes 94</td>
<td>yes 98</td>
<td>yes 98</td>
</tr>
<tr>
<td>SD</td>
<td>yes</td>
<td>yes 9/99</td>
<td>yes 9/99</td>
<td></td>
</tr>
<tr>
<td>TN</td>
<td>yes</td>
<td>yes 98</td>
<td>yes 9/99</td>
<td></td>
</tr>
<tr>
<td>TX</td>
<td>yes</td>
<td>yes 98</td>
<td>yes 98</td>
<td></td>
</tr>
<tr>
<td>UT</td>
<td>yes</td>
<td>yes 7/99</td>
<td>yes 7/99</td>
<td></td>
</tr>
<tr>
<td>VT</td>
<td>yes</td>
<td>yes 8/99</td>
<td>yes 8/99</td>
<td></td>
</tr>
<tr>
<td>VA</td>
<td>yes</td>
<td>yes 9/99</td>
<td>yes 9/99</td>
<td></td>
</tr>
<tr>
<td>WA</td>
<td>yes</td>
<td>yes 97</td>
<td>yes 97</td>
<td></td>
</tr>
<tr>
<td>WV</td>
<td>yes</td>
<td>yes 97</td>
<td>yes 98</td>
<td></td>
</tr>
<tr>
<td>WI</td>
<td>yes</td>
<td>yes 97</td>
<td>yes 97</td>
<td></td>
</tr>
<tr>
<td>WY</td>
<td>yes</td>
<td>born after 1/96</td>
<td>yes 99/99</td>
<td>yes 98</td>
</tr>
</tbody>
</table>

**An empty box in this table means “NO”**
Unprotected people ...

Two deaths in a nursing home ignite pneumococcal vaccine campaign

The Immunization Action Coalition collects stories and case reports such as the one below of people who have suffered or died from vaccine-preventable diseases. Stories and case reports can help get out an urgent message about the importance of vaccination. Please help! Send us stories, news items, or case reports about ANY vaccine-preventable disease. E-mail these items to the Immunization Action Coalition to <deborah@immunize.org> or fax your information to 651-647-9131.

Editors' note: Pneumococcal disease causes approximately 40,000 deaths, 500,000 cases of pneumonia, and 50,000 cases of bacteremia each year in the United States. A 1997 CDC survey indicated that only 45% of adults 65 years of age and older have received their recommended dose of pneumococcal vaccine (MMWR, October 2, 1998, vol. 47, no.38).

The following article is from the Texas Department of Health's newsletter, Accent on Health, March 10, 1997.

According to Devora Goodnight, it wasn’t just luck that only two people died in a recent outbreak of deadly pneumococcal disease where she works at the Houston County Nursing Home in Crockett. What undoubtedly saved lives when the outbreak began was a combination of the nursing home staff’s recognizing the seriousness of the outbreak and their getting an immediate response from experts at the Texas Department of Health (TDH).

But perhaps the most decisive single factor was the quick immunization of all potential patients with a vaccine which often is overlooked by physicians and patients alike.

After two patients died of streptococcal pneumonia infections and one other was stricken, Goodnight said, “We knew we had a situation that might cost many of our residents’ lives if it got further out of hand. We had never had anything like this happen before and didn’t even know what to expect if we called TDH for help. But we knew we would most likely lose more of our ‘family’ if we didn’t.”

At TDH’s Infectious Disease Control and Surveillance Division, epidemiologist Beverly Ray said that Goodnight and the home’s nursing director Debbie Hargrove showed “the highest standard of concern for their residents.”

Ray explained that although outbreaks of pneumococcal disease caused by Streptococcus pneumoniae bacteria are rare, the bacteria spread rapidly among immunized people whose health may already be compromised. People in good health with normal immune systems are not as likely to develop infections, but ill people, such as elderly nursing home residents with existing problems, are especially at risk of developing pneumonia after exposure to the bacteria.

According to Ray, Streptococcus pneumoniae causes about half a million individual cases of pneumonia, some 3,000 cases of meningitis and about seven million ear infections in the United States every year. The most susceptible people are the elderly and ill, such as those at the Crockett nursing home, infants and toddlers, people with chronic health conditions such as diabetes or emphysema, and people without spleens or with weakened immune systems. Outbreaks of the disease occur most commonly during the winter months, among nursing home patients, residents in prisons, and other groups who share close living quarters and often breathe the same air.

The U.S. Centers for Disease Control and Prevention recommends that all people 65 years of age or older receive one dose of pneumococcal vaccine. Those at greatest risk for serious complications from pneumococcal disease need to receive a second dose five years later. The vaccine is effective against at least 23 different strains of streptococcal bacteria and is fast acting. However, Ray said that in a recent survey of Texans 65 and older, only 42 percent said they had been vaccinated against bacterial pneumonia.

**Pneumococcal vaccine is unbelievably underused.**

Ray said, “This vaccine is one of the most effective, fastest-acting vaccines we have for averting outbreaks among such groups as nursing home residents, yet it is unbelievably underused. We hope that physicians will offer the vaccine more often to their own patients who may be at risk, and that more patients or family members will remember to ask for the vaccine if they have not already had it.”

After TDH received the Crockett nursing home’s call for help on Jan. 23, Ray and a team of other epidemiology staff drove directly to Crockett to begin taking blood samples from about 90 nursing home residents and staff and obtaining permission to begin vaccinating as many of the residents as possible. Only 14 of 88 residents had previously been immunized. Vaccinations began the following morning, Jan. 24.

According to Hargrove, she and others on the nursing home staff “were amazed at how quickly TDH brought the outbreak under control.”

**Only 14 of the 88 residents had previously been immunized.**

Although two patients out of the first three diagnosed with pneumococcal disease died, the remaining victim of the outbreak survived and has recovered. The vaccines which the other residents received have begun protecting the home’s residents from further infections. For a few days after the residents were vaccinated, some of their visiting friends and family members were advised to take antibiotics as an additional precaution against more pneumococcal infections, but no other cases occurred.

Goodnight said that the loss of the two residents who died from pneumococcal disease has been hard on the other residents and the staff alike. “They were part of our family. We always try to operate as one big family here, and a death is personal to all of us. We are just very, very grateful that help was there when we needed it to prevent even more tragedies,” she said.

**Many people under 65 need pneumococcal vaccine, too!**

For a copy of “Pneumococcal vaccine: who needs it and who needs it again?” visit www.immunize.org/catg.d/2015pne.htm or see item #P2015 on page 27.
# Summary of Rules for Childhood Immunization*

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Ages usually given, other guidelines</th>
<th>If child falls behind - minimum intervals</th>
<th>Contraindications (Remember, mild illness is not a contraindication.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>DTap contains acellular pertussis</td>
<td>DTap is preferred over DTP for all doses in the series. Give at 2m, 4m, 6m, 15-18m, 4-6yrs of age. May give #1 as early as 6wks of age. May give #4 as early as 12m of age if 5m has elapsed since #3 and the child is unlikely to return at age 15-18m. If started with DTP, complete the series with DTap. Do not give DTap or DTP to children &gt; 7yrs of age (give Td). DTap/DTP may be given with all other vaccines but at a separate site. It is preferable but not mandatory to use the same DTap product for all doses.</td>
<td>#2 &amp; #3 may be given 4wks after previous dose. #4 may be given 6m after #3. If #4 is given before 4th birthday, wait at least 6m for #5. If #4 is given after 4th birthday, #5 is not needed. Don’t restart series, no matter how long since previous dose.</td>
<td>(DTap and DTP have the same contraindications and precautions.) Anaphylactic reaction to a prior dose or to any vaccine component. Moderate or severe acute illness. Don’t postpone for minor illness. Previous encephalopathy within 7 days after DTP/DTap. Unstable progressive neurologic problem.</td>
</tr>
<tr>
<td>DT contains whole-cell pertussis</td>
<td>Give IM</td>
<td>For children who have fallen behind, use information in box directly above.</td>
<td>Anaphylactic reaction to a prior dose or to any vaccine component. Moderate or severe acute illness. Don’t postpone for minor illness.</td>
</tr>
<tr>
<td>Td</td>
<td>Give IM</td>
<td>For those never vaccinated or behind, or if the vaccination history is unknown: give dose #1 now; dose #2 is given 4wks later; dose #3 is given 6m after #2; and then boost every 10 years.</td>
<td>Anaphylactic reaction to a prior dose or to any vaccine component. Moderate or severe acute illness. Don’t postpone for minor illness.</td>
</tr>
<tr>
<td>Polio IPV and OPV</td>
<td>Give IPV SQ or IM</td>
<td>Give IPV at 2m, 4m, 6-18m, and 4-6yrs of age. Give IPV for doses #1 and #2 (except in special circumstances, e.g., parent’s refusal, imminent travel to polio-endemic area). ACIP says for dose #3, give OPV at 12-18m, and for dose #4, give OPV at 4-6yrs. An all-IPV schedule is also acceptable. If an all-IPV or all-OPV schedule is used, dose #3 may be given as early as 6m of age.</td>
<td>#1, #2, &amp; #3 (IPV or OPV) should be separated by at least 4wks. All IPV: a 6m interval is preferred between dose #2 and #3 for best response. #4 (IPV or OPV) is given between 4-6yrs of age. If #3 of an all-IPV or all-OPV series is given at ≥ 4yrs of age, dose #4 is not needed. Children who receive any combination of IPV and OPV doses must receive all 4 doses, regardless of the age when first initiated. Don’t restart series, no matter how long since previous dose.</td>
</tr>
<tr>
<td>Varicella Var</td>
<td>Give SQ</td>
<td>Routinely give at 12-18m. Vaccinate all children &gt;12m of age including all adolescents who have not had prior infection with chickenpox. If Var and MMR (and/or yellow fever vaccine) are not given on the same day, space them ≥28d apart. Var may be given with all other vaccines but at a separate site.</td>
<td>Do not give to children &lt;12m of age. Susceptible children &lt;13yrs of age receive 1 dose. Susceptible persons ≥13 yrs of age receive 2 doses ≥4wks apart. Don’t restart series, no matter how long since previous dose.</td>
</tr>
</tbody>
</table>

* Hepatitis A, influenza, pneumococcal, and Lyme disease vaccines are indicated for many children and teens, so make sure you provide these vaccines to at-risk children. The newer combination vaccines are not listed on this table but may be used whenever administration of any component is indicated and none is contraindicated.

Read the package inserts. For full immunization information, see recent ACIP statements published in the MMWR, and for the latest recommendations of the AAP’s Committee on Infectious Diseases, see the AAP’s 1997 Red Book and the journal, Pediatrics.
### Summary of Rules for Childhood Immunization (continued)

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Ages usually given and other guidelines</th>
<th>For children fallen behind (minimum intervals)</th>
<th>Contraindications (Remember, mild illness is not a contraindication.)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MMR</strong></td>
<td>Give #1 at 12-15m. Give #2 at 4-6yrs.</td>
<td>• 2 doses of MMR are recommended for all children &lt; 18 yrs of age.</td>
<td>• Anaphylactic reaction to a prior dose or to any vaccine component.</td>
</tr>
<tr>
<td></td>
<td>• Make sure that all children (and teens) over 4-6 yrs have received both doses of MMR.</td>
<td>• Give whenever behind. Exception: If MMR and Var (and/or yellow fever vaccine) are not given on the same day, space them ≥28d apart.</td>
<td>• Pregnancy or possible pregnancy within next 3m (use contraception).</td>
</tr>
<tr>
<td></td>
<td>If a dose was given before 12m of age, give #1 at 12-15m of age with a minimum interval of 4wks between these doses.</td>
<td>• There should be a minimum interval of 28d between MMR #1 and MMR #2.</td>
<td>• Moderate or severe acute illness. Don’t postpone for minor illness.</td>
</tr>
<tr>
<td></td>
<td>• If MMR and Var (and/or yellow fever vaccine) are not given on the same day, space them ≥28d apart.</td>
<td>• Dose #2 can be given at any time if at least 28d have elapsed since dose #1, and both doses are administered after 1 year of age.</td>
<td>• If blood, plasma, or immune globulin were given in past 11 months, see ACIP recs or 1997 Red Book (p.353) re: time to wait before vaccinating.</td>
</tr>
<tr>
<td></td>
<td>• May give with all other vaccines but at a separate site.</td>
<td>• Don’t restart series, no matter how long since previous dose.</td>
<td>• HIV is NOT a contraindication unless severely immunocompromised.</td>
</tr>
</tbody>
</table>

**Hib**

<table>
<thead>
<tr>
<th>Give SQ</th>
<th>Hib/TITER (HbOC) &amp; ActHib (PRP-T): give at 2m, 4m, 6m, 12-15m.</th>
<th>Rules for all Hib vaccines:</th>
<th>• Anaphylactic reaction to a prior dose or to any vaccine component.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>• Dose #1 of Hib vaccine may be given as early as 6wks of age but not earlier.</td>
<td>• The last dose (booster dose) is given no earlier than 12 months of age and a minimum of 2 months since the previous dose.</td>
<td>• Moderate or severe acute illness. Don’t postpone for minor illness.</td>
</tr>
<tr>
<td></td>
<td>• May give with all other vaccines but at a separate site.</td>
<td>• For children &gt; 15m and less than 5yrs who have NEVER received Hib vaccine, only 1 dose is needed.</td>
<td>• May give with all other vaccines but at a separate site.</td>
</tr>
<tr>
<td></td>
<td>• All Hib products licensed for the primary series are interchangeable.</td>
<td>• Don’t restart series, no matter how long since previous dose.</td>
<td>• Hepatitis B vaccine brands are interchangeable.</td>
</tr>
<tr>
<td></td>
<td>• Any Hib vaccine may be used for the booster dose.</td>
<td><strong>Rules for Hib vaccine: (HibTITER) &amp; PRP-T (ActHib) only:</strong></td>
<td>• Anaphylactic reaction to a prior dose or to any vaccine component.</td>
</tr>
<tr>
<td></td>
<td>• Hib is not routinely given to children &lt; 5yrs of age.</td>
<td>• #2 and #3 may be given 4 wks after previous dose.</td>
<td>• Moderate or severe acute illness. Don’t postpone for minor illness.</td>
</tr>
<tr>
<td></td>
<td><strong>Hep-B</strong></td>
<td><strong>Hep-B</strong></td>
<td><strong>Rota-virus</strong></td>
</tr>
<tr>
<td><strong>Hep-B</strong></td>
<td>Vaccinate all infants at 0-2m, 1-4m, 6-18m.</td>
<td><strong>Vaccinate all children 0-18 years of age.</strong></td>
<td><strong>Give at 2m, 4m, and 6m.</strong></td>
</tr>
<tr>
<td></td>
<td>• Vaccinate all children 0-18 years of age.</td>
<td>• For older children/teens, spacing options include: 0m, 1m, 6m, 9m, 2m, 4m, or 0m, 1m, 4m.</td>
<td>• Minimum interval is 3wks between doses.</td>
</tr>
<tr>
<td></td>
<td>• Children who were born or whose parents were born in countries of high HBV endemicity or who have other risk factors should be vaccinated as soon as possible.</td>
<td>• 3-dose series can be started at any age.</td>
<td>• Moderate or severe acute illness, including persistent vomiting. Don’t postpone for minor illness.</td>
</tr>
<tr>
<td></td>
<td>• If mother is HBsAg positive: give HBIG and hep-B #1 within 12 hrs of birth, #2 at 1-2m, and #3 at 6m of age.</td>
<td>• Minimum spacing for children and teens: 4wks between #1 &amp; #2, and 2m between #2 &amp; #3. Overall there must be 4m between #1 and #3.</td>
<td>• Anaphylactic reaction to a prior dose or to any vaccine component.</td>
</tr>
<tr>
<td></td>
<td>• If mother’s HBsAg status is unknown: give hep B #1within 12hrs of birth, #2 at 1-2m, and #3 at 6m of age.</td>
<td>• Dose #3 should not be given earlier than 6 months of age.</td>
<td>• Known or suspected altered immunity, including infants born to HIV+ mothers unless it is known that the child is not HIV infected.</td>
</tr>
<tr>
<td></td>
<td>• If mother is later found to be HBsAg-positive, her infant should receive the additional protection of HBIG within the first 7 days of life.</td>
<td><strong>Dosing of hepatitis B vaccines:</strong></td>
<td>• For infants with pre-existing chronic GI conditions, see ACIP statement.</td>
</tr>
<tr>
<td></td>
<td>• May give with all other vaccines but at a separate site.</td>
<td>For Engerix-B, use 10µg (0.5ml) for 0 through 19 yrs of age.</td>
<td><strong>Thank you to the following individuals for their review:</strong> William Atkinson, MD, Harold Margolis, MD, Linda Moyer, RN, Jane Seward, MBBS, Robert Sharrar, MD, Thomas Vernon, MD, Richard Zimmerman, MD. Final responsibility for errors lies with the editors.</td>
</tr>
<tr>
<td></td>
<td>• Hepatitis B vaccine brands are interchangeable.</td>
<td>For Recombivax HB, use 5µg (0.5ml) for 0 through 19 yrs of age.</td>
<td>This table is revised yearly. The most recent edition of this table is available on our website at &lt;www.immunize.org&gt;</td>
</tr>
</tbody>
</table>

---

The Immunization Action Coalition developed this table to combine the recommendations for childhood immunization onto one page and to assist health care workers in determining the appropriate use and scheduling of vaccines. It can be posted in immunization clinics or clinicians’ offices. Comments? e-mail: medinfo@immunize.org, call: 651-647-9009, or mail to IAC at 1573 Selby Avenue, St. Paul, MN 55104.
Children should get 3 doses of rotavirus vaccine:

- One dose at 2 months of age
- One dose at 4 months of age
- One dose at 6 months of age

Catch-up: If your child misses a dose or gets behind schedule, get the next dose as soon as you can. There is no need to start over.

However, children should not get rotavirus vaccine after their first birthday. A child who has not gotten the first dose by 7 months of age should not get the vaccine.

Note: Children who are born during the summer or fall may need to get rotavirus vaccine at slightly younger ages than usual to be sure they are protected during the winter rotavirus season. Your doctor or nurse can give you details.

Rotavirus vaccine may be given at the same time as other vaccines.

• Babies who have passed their first birthday should not get rotavirus vaccine.
• Babies 7 months of age or older who have not gotten at least one dose of rotavirus vaccine should not get the vaccine.
• Babies who have ever had a serious allergic reaction to a previous dose of rotavirus vaccine should not get another dose. Babies who have ever had a serious allergic reaction to certain antibiotics, or to monosodium glutamate, should not get the vaccine.
• Babies with certain diseases of the stomach or intestines should not get rotavirus vaccine.

• For babies with ongoing diarrhea, check with their doctor about whether they should get rotavirus vaccine.

• For babies who are unable to fight serious infections because of
  - HIV/AIDS, or any other disease that affects the immune system
  - treatment with drugs such as long-term steroids
  - any kind of cancer
  - cancer treatment with x-rays or drugs,
  should check with their doctor about whether they should get rotavirus vaccine.

• Babies who are moderately or severely ill at the time the vaccination is scheduled should usually wait until they recover before getting rotavirus vaccine.

• If your baby was premature, check with your doctor before getting rotavirus vaccine.

Ask your doctor or nurse for details.

5 What are the risks from rotavirus vaccine?

A vaccine, like any medicine, is capable of causing serious problems, such as severe allergic reactions. The risk of a vaccine causing serious harm, or death, is extremely small.

In studies that have been done so far rotavirus vaccine has been associated only with mild problems. The risk from rotavirus vaccine is much smaller than the risk from the disease.

Most babies who get rotavirus vaccine do not have any problems with it.

Mild problems
• mild fever (over 100°F): up to 15% of children getting the vaccine
• moderate fever (over 102°F): about 1% of children getting the vaccine
• less appetite, tiredness, fussiness

If these problems happen, it is usually 3-5 days after vaccination.

6 What if there is a moderate or severe reaction?

What should I look for?
Any unusual condition, such as a high fever or behavior changes. Signs of a serious allergic reaction can include difficulty breathing, hoarseness or wheezing, hives, paleness, weakness, a fast heart beat or dizziness, occurring within a few minutes to a few hours after the vaccination. A high fever or seizure, should it occur, would be within a week after the vaccination.

What should I do?
• Call a doctor, or get the person to a doctor right away.
• Tell your doctor what happened, the date and time it happened, and when the vaccination was given.
• Ask your doctor, nurse, or health department to file a Vaccine Adverse Event Reporting System (VAERS) form, or call VAERS yourself at 1-800-822-7967.

7 How can I learn more?
• Ask your doctor or nurse. They can give you the vaccine package insert or suggest other sources of information.
• Call your local or state health department.
• Contact the Centers for Disease Control and Prevention (CDC):
  - Call 1-800-232-2522 (English)
  - Call 1-800-232-0233 (Español)
  - Visit the National Immunization Program’s website at http://www.cdc.gov/nip
What would happen if we stopped vaccinations?

The viruses and bacteria that cause vaccine-preventable disease and death still exist. They have not disappeared. Vaccines have dramatically reduced the number of people who get infectious diseases and the complications these diseases produce. Without vaccines, epidemics of vaccine-preventable diseases would return, resulting in increased illness, disability, and death. Vaccine preventable diseases also have a costly impact, resulting in doctors’ visits, hospitalizations, and lost time from work for many parents.

Polio

Polio virus causes acute paralysis that can lead to permanent physical disability and even death. Before polio vaccine was available, annual epidemics of polio often left thousands of victims—mostly children—in braces, crutches, wheelchairs, and iron lungs.

Prior to the availability of polio vaccines, between 13,000 and 20,000 cases of paralytic poliomyelitis were reported each year in the United States.

Development of polio vaccines and implementation of polio immunization programs have eliminated paralytic polio caused by wild polio viruses in the U.S. and the entire Western hemisphere.

In 1996, as a result of global immunization efforts to eradicate the disease, there were only 3,500 documented cases of polio in the world. However, in today’s global economy, importations of wild polio virus are only an airplane ride away.

In 1994, wild polio virus was imported to Canada from India, but high vaccination levels prevented it from spreading in the population.

If we were to discontinue polio vaccination in the U.S., immunity to polio would decline, leading to the risk of polio epidemics similar to those that occurred in the past.

Measles

Before measles immunizations were available, nearly everyone in the U.S. got measles. There were approximately 3 to 4 million measles cases each year. An average of 450 measles-associated deaths were reported each year between 1953 and 1963.

In industrialized countries, up to 20 percent of persons with measles are hospitalized, and 7 percent to 9 percent suffer from complications such as pneumonia, diarrhea, or ear infections. Some persons with measles develop encephalitis, resulting in brain damage. It is estimated that as many as 1 of every 1,000 persons with measles will die.

Widespread use of measles vaccine has led to a greater than 95 percent reduction in measles, compared with the pre-vaccine era.

Measles virus is common throughout the world and is frequently imported into the U.S. In 1996, 47 cases were known to have been imported by people traveling to the U.S. from other countries. In the first three months of 1997, all U.S. measles cases reported have been linked to imported cases.

According to the World Health Organization, 1.1 million deaths occurred worldwide from measles in 1995. If vaccinations were stopped, 2.7 million measles deaths could be expected.

Stopping measles vaccination would be expected to lead to massive epidemics similar to those that occurred in the pre-vaccine era. Between 1989 and 1991, the number of reported measles cases in the U.S. increased sharply, with more than 55,000 cases, 11,000 hospitalizations, and 120 deaths reported. The major cause of this epidemic was low rates of vaccination among preschool children. The risk of measles in preschool-age African-American and Hispanic children was 8 to 10 times higher than that in other children.
higher than that of white children, due to lower vaccination rates in these children.

**Haemophilus influenzae type b (Hib) meningitis**

Before Hib immunizations became available, Hib was the most common cause of bacterial meningitis in U.S. infants and children. Before the vaccine was developed, there were approximately 20,000 invasive Hib cases annually. Approximately two-thirds of the annual cases were meningitis. Up to 8,000 additional cases of life-threatening invasive Hib disease—bacteremia, pneumonia, or epiglottitis—also occurred annually. One of every 200 U.S. children less than 5 years of age got Hib disease. Hib meningitis killed 600 children each year, and left many survivors with deafness, seizures, or mental retardation.

Since introduction of conjugate Hib vaccine in December 1987, the incidence of Hib has declined by 97-99 percent. Fewer than 10 fatal cases of invasive Hib disease were reported in 1995.

This preventable disease was still a common, devastating illness as recently as 1990. Now, most pediatricians just finishing training have never seen a case. If we were to discontinue immunization, we would likely soon return to the pre-vaccine numbers of invasive Hib disease cases and deaths.

**Pertussis (whooping cough)**

Before pertussis immunizations were available, nearly all children developed pertussis. In the U.S., prior to pertussis immunization, between 150,000 and 260,000 cases of pertussis were reported each year, with up to 9,000 pertussis-related deaths.

Pertussis can be a severe illness, resulting in prolonged coughing and vomiting spells that can last for weeks. These spells can make it difficult for a child to eat, drink, and breathe. In infants, it can also cause pneumonia and lead to brain damage, seizures, and mental retardation.

The newer pertussis vaccine (acellular or DTaP) that has been available for use in the United States since 1991 is also effective and is associated with fewer mild and moderate adverse reactions when compared with the older (whole-cell DTP) vaccine. In the 1970s, Sweden and Japan’s use of pertussis vaccine dropped significantly for various periods of time due to adverse publicity about the older vaccine. These countries experienced a resulting resurgence in pertussis disease.

During the 1970s, widespread concerns about the safety of pertussis immunization led to a rapid fall in immunization levels in the United Kingdom. Within the next several years, a series of pertussis epidemics occurred. More than 100,000 cases and 36 deaths due to pertussis were reported during an epidemic in the mid 1970s.

In Japan, pertussis vaccination coverage fell from 80 percent in 1974 to 20 percent in 1979. An epidemic occurred in 1979, resulting in more than 13,000 cases and 41 deaths.

Pertussis cases occur throughout the world. If we were to discontinue pertussis immunizations in the U.S., we would experience a massive resurgence of pertussis disease. A very recent study found that, in eight countries where immunization coverage was reduced, incidence rates of pertussis surged to 10 to 100 times the rates in countries where vaccination rates were sustained.

**Rubella**

While rubella is usually mild in children and adults, up to 90 percent of infants born to mothers infected with rubella during the first trimester of pregnancy will develop congenital rubella syndrome (CRS), resulting in heart defects, cataracts, mental retardation, and/or deafness.

In 1964–1965, before rubella immunization was used routinely in the U.S., there was an epidemic of rubella that resulted in an estimated 20,000 infants born with CRS, with 2,100 neonatal deaths and 11,250 miscarriages. Of the 20,000 infants born with CRS, 11,600 were deaf, 3,580 were blind, and 1,800 were mentally retarded.

Many developing countries do not include rubella in the childhood immunization schedule. In 1996, two outbreaks of rubella in young adults occurred among recently arrived immigrants who were not protected against rubella. At least four pregnant women contracted rubella during this outbreak.

If immunity to rubella were to decline, rubella would once again return, resulting in pregnant women becoming infected and then giving birth to infants with CRS. Incidence of CRS declined dramatically with widespread use of rubella vaccine.

The above information covers five of the 11 vaccine-preventable diseases for which children are routinely vaccinated. Information on the importance of vaccinating against diphtheria, tetanus, hepatitis B, chickenpox, and mumps will appear in the fall/winter 1999 issue of NEEDLE TIPS.
Do you spend too much time fishing for practical vaccine information?

IAC EXPRESS delivers vaccine information directly to your e-mail box

- ACIP statements
- *MMWR* vaccine articles
- FDA: new vaccines, treatments
- CDC: hot topics, vaccine safety
- vaccine news in the mainstream media
- calendar of vaccine events
- stories of people with vaccine-preventable diseases

**SIGN UP!**

Send an e-mail message to express@immunize.org
Enter the word SUBSCRIBE in the "Subject:" field.

To see what's already been published, visit www.immunize.org/express/
If you have sex, read this...

And stop a killer STD from sneaking up on you!

This article, written by Lynda Liu, is reprinted from Mademoiselle, February 1999

Just a few months after she graduated from college, 22-year-old Wendy Marx began to feel so bone-tired that she could barely make it to her brand-new job as an office manager at a San Francisco marketing firm. She ate little or no food and became nauseated when she did force down a meal. Still, it wasn’t until a coworker pointed out that her eyes were slightly yellowish that she finally saw a doctor. Blood tests revealed that she had hepatitis B, a potentially deadly liver infection.

Wendy was admitted to the hospital, but the virus was already out of control, attacking and killing her liver cells. As a last-ditch effort, doctors tried an experimental drug; it failed. Toxins in her bloodstream - which a normally functioning liver would filter out - caused her brain to swell, and four weeks after she was diagnosed, Wendy slipped into a coma. No one was even sure how she’d gotten sick.

Silent but Deadly

You may not think of hepatitis B as a sexually transmitted disease (STD), but it’s 100 times more contagious than HIV, and about one in every 20 Americans will be infected at some point in their life. In most adults, the immune system springs into action at the first contact with the virus, killing it before it does any serious damage to the liver, and spurring the body to manufacture antibodies to ward off the disease in the future.

But in 5 to 10 percent of the people infected - more than a million Americans - the disease takes hold despite the immune system’s best efforts. Those people, called chronic carriers, have the disease for life - even months to a year after they’ve been exposed to blood – other common ways to come in contact with infected blood. For the same reason, unsterilized manicure instruments, body-piercing equipment and tattoo and electrolysis needles could be potential carriers.

Protection by Injection

There’s reassuring news, however: “Hepatitis B is entirely preventable,” says Henry C. Bodenheimer, Jr., MD, medical director of liver diseases at the Recanati Miller Transplantation Institute at Mt. Sinai Medical Center in New York. An effective vaccine can be given in three shots over six months. Some insurance companies will cover the cost, around $200. Dr. Wexler says that, for sexually active young women, the vaccine “is an excellent insurance policy” against hepatitis B. (But it doesn’t mean saying so long to safe-sex practices, both she and Dr. Bodenheimer point out; plenty of other STDs are lurking.)

For Wendy Marx, it was far too late for a vaccine. Her failed liver had to be replaced by a transplant. And since hepatitis B can’t be cured, the virus was still in her system, causing damage. Two years later, the transplanted liver failed, too. Wendy, now 31, was lucky – she got a second transplant and now her life seems relatively normal. “I work long hours,” she says. “I go to the gym. I have a boyfriend.” But she also lives with the possibility that the hepatitis could flare up yet again.

“You don’t want to go through what I’ve been through,” she says. “It’s a hell of a lot easier to get the three shots. My life would be entirely different if I had.”

Hepatitis B is especially dangerous because chronic carriers are likely to have no recognizable symptoms - and so they may never suspect that they’re spreading the disease. And, unfortunately, though medication can help control hepatitis B in some patients, there is no cure.

A Disease That Can Live on a Doorknob

Hepatitis B is classified as an STD because, among adults who get it, it’s transmitted through unprotected sex, says Deborah Wexler, MD, executive director of the Immunization Action Coalition in St. Paul, MN. But Wendy Marx was positive that this hadn’t been her mistake; nor did she use intravenous drugs or work at a job where she was exposed to blood - other common ways to catch the disease.

Scarily, the answer to Wendy’s mystery may lie in the fact that hepatitis B can survive for up to a month outside the body, on surfaces such as doorknobs and tabletops (and, yes, toilet seats). The virus is transmitted through body fluids like semen, vaginal secretions and blood, so it’s extremely unlikely that a toilet seat poses any danger, says Dr. Wexler.

But, theoretically, you could contract the disease by touching a doorknob that harbored the virus and then rubbing your eye with your hand. (She emphasizes that it’s a remote possibility.) The far more dangerous culprits are personal items like toothbrushes and razors, which might

Have you seen these symptoms?

The symptoms that appear when you’re first infected with hepatitis B are actually a sign that your immune system is fighting off the disease, says Paul Martin, MD, director of hepatology (liver studies) at the UCLA School of Medicine. See your doctor if you experience any of the following:

- flu-like symptoms such as loss of appetite, nausea, vomiting and fever
- feeling tired or weak for weeks or even months
- pain in the area of the liver (the right side of your abdomen)
- dark, tea-colored urine
- jaundice (yellowing of the skin or eyes)
not final, it appears that ACIP will recommend revaccination with most vaccines after transplant. Revaccination with inactivated vaccines (Td, hepatitis B, IPV, Hib, pneumococcal, and influenza) will probably be recommended at 12 months post-transplant. MMR will probably be recommended at 24 months or more post-transplant, but only for persons who are determined not to be immunosuppressed and not experiencing graft-versus-host disease. More definitive information will be available later this year after the guidelines are finalized.

Can influenza and pneumococcal vaccine be put together in the same syringe?

Absolutely not. No vaccines should ever be mixed in the same syringe unless the combination has been specifically approved by the FDA. At present, only Pasteur Mérieux Connaught's DTaP and Hib vaccines (as TriHIBit) have been approved for mixing in the same syringe but only for the fourth dose.

After a blood transfusion, which vaccines are contraindicated and for how long?

Measles, mumps, and rubella vaccines should not be given for at least 6 months following a transfusion of whole blood. A table in the 1998 MMR ACIP statement (MMWR 1998;47[RR-8]) lists the recommended delay following other antibody-containing blood products. Varicella vaccine should be delayed for at least 5 months after a transfusion of whole blood. Inactivated vaccines (DTaP, Hib, etc.) and live oral vaccines (OPV, rotavirus) may be given at any time before or after receipt of blood products.

What vaccines can a child with severe combined immunodeficiency syndrome (SCIDS) receive?

Children with SCIDS may be given inactivated vaccines (i.e., DTaP, Hib, hepatitis B, IPV, influenza, and, if indicated, pneumococcal and hepatitis A). They should not be given live vaccines (MMR, oral polio, varicella, and rotavirus).

What bird is getting run over all the time?

A rail!

We have a patient who received tetanus toxoid 3 weeks ago. This patient is traveling internationally and needs diphtheria vaccine. What should we do?

Single antigen tetanus toxoid has almost no indications. Persons who require tetanus vaccination should always receive combined tetanus and diphtheria toxoids (Td). Single antigen diphtheria toxoid is not generally available. Because of the concern of local adverse reactions, it would be preferable to delay Td for a few months after the tetanus toxoid. However, if travel is imminent, particularly to an area where diphtheria is common (such as countries of the former Soviet Union), Td should be administered. The person should be informed about the possibility of a local reaction and advised about measures to decrease discomfort if a local reaction should occur.

Polio

What changes did the ACIP make in 1999 to the polio vaccine recommendations?

The ACIP, the American Academy of Pediatrics (AAP), and the American Academy of Family Physicians (AAFP) recommend IPV be used for the first two doses of the polio vaccination series. The use of OPV for the first two doses of the series is no longer recommended except in special circumstances, primarily when the parents will not accept the increased number of injections required when using IPV. IPV is also recommended for children traveling to polio-endemic countries except when travel will occur in less than 4 weeks.

Is there any reason not to use an all-IPV schedule?

A schedule that includes only IPV is an acceptable alternative to the sequential IPV-OPV schedule. It is also recommended for immunodeficient persons and their household contacts.

For immigrant children who need to receive polio vaccine (no past records available), should we use OPV or IPV?

The sequential IPV-OPV polio vaccination schedule is routinely recommended for children, which includes children whose vaccination history is unknown. As noted in an earlier question, OPV may be used for the first two doses if the parents will not accept an additional injection. If using the sequential schedule, 4 doses of polio vaccine must be administered. If using an all-OPV or an all-IPV schedule, only 3 doses are needed if the child receives dose #3 after the fourth birthday.
a single dose of any Hib conjugate vaccine. Hib vaccine is not routinely recommended for persons 5 years of age or older.

**Does anyone 5 years of age or older need to receive Hib vaccine?**

There are few data on the efficacy of Hib vaccine in persons 5 years of age or older. ACIP recommends consideration of Hib vaccination for unvaccinated persons 5 years of age and older with anatomic or functional asplenia, sickle-cell anemia, or HIV infection (MMWR 1993;42[RR-4]:8; MMWR 1991;40[RR-12]:29). A single dose of any licensed conjugate vaccine is probably sufficient in most cases (using the dose recommended by the manufacturer for a child). The 1997 AAP Red Book suggests 2 doses separated by 1–2 months for persons with HIV infection or IgG2 immune deficiency.

---

**Varicella**

*by William L. Atkinson, MD, MPH*

**Can varicella vaccine be used postexposure to prevent disease?**

Several studies have shown that administration of varicella vaccine within 72 hours, and possibly up to 5 days after exposure to varicella, may prevent or significantly reduce the severity of varicella. ACIP is currently developing a revised statement on varicella that will recommend vaccination of susceptible persons following exposure to varicella. Vaccine should be administered as soon as possible after exposure, preferably within 72 hours. Limited data indicate that vaccination 5 days or more after exposure is less likely to prevent or modify the disease, however, it will provide future protection if the exposed person has not been infected.

**If a child breaks out in 5–10 maculopapular spots 2 weeks following varicella vaccination, can s/he go to school?**

Transmission of varicella virus is a rare event, and appears to occur only when the vaccinated person develops a vesicular rash. A maculopapular rash 2 weeks after varicella vaccine may not have been caused by the vaccine. If the rash were caused by the vaccine, the risk of transmission is very small. The child’s activities, including attendance at school, do not need to be restricted.

**If a vaccinated child gets 5–10 vesicular lesions 2 weeks after vaccination, can s/he attend school?**

You cannot distinguish a mild case of varicella disease from a rash caused by the vaccine. The child may have been infected with varicella at about the same time s/he was vaccinated. The conservative approach would be to treat the child as if s/he had chickenpox and restrict his/her activities until all the lesions crust over.

**If a child gets breakthrough varicella infection, ~50 lesions, can s/he go to school?**

Breakthrough varicella represents replication of wild varicella virus in a vaccinated person. Although most breakthrough disease is very mild, the child is contagious and activities should be restricted to the same extent as an unvaccinated person with varicella disease.

**Under what circumstances would you obtain a varicella titer after vaccination?**

Postvaccination serologic testing is not recommended in any group, including vaccinated health care workers.

**Can a pregnant health care worker with a history of varicella infection care for a patient with varicella? Is it possible for her to have a declining titer, thus making her susceptible to the virus again?**

Persons with a reliable history of varicella can be considered to be immune. Immunity following disease or vaccination is probably life-long. More than one primary infection with varicella is unusual.

---

**Measles, mumps, rubella**

*by William L. Atkinson, MD, MPH*

**I have adult patients going back to school who must show proof of MMR vaccine and are unable to retrieve their immunization records. What are my options?**

Your options are to either bring the person into compliance with the school entry requirement by vaccinating or to perform serologic testing for all the antigens for which documented immunity is required. There is no evidence that adverse reactions are increased when MMR is given to a person who is already immune to one or more of the components of the vaccine.

**In the last issue of NEEDLE TIPS you said that if a pregnant woman had a positive rubella titer in the past, and now has a negative rubella titer, she would not need another MMR vaccination. Doesn’t the negative rubella titer mean her immunity has waned and she needs a booster dose?**

Rubella antibody levels may decline with time, and may even fall below the level of detection of standard screening tests. However, data from surveillance of rubella and congenital rubella syndrome suggest that waning immunity with increased susceptibility to rubella disease does not occur (MMWR 1998;47[RR-8]:14). Studies of persons who have “lost” detectable rubella antibody indicate that almost all had antibody detectable by more sensitive tests, or demonstrated a booster-type response (absence of IgM antibody and a rapid rise in IgG antibody) after revaccination.

---

**Rotavirus**

*by William L. Atkinson, MD, MPH*

**When will the ACIP statement on rotavirus vaccine be released?**

The rotavirus ACIP statement should be published by April 1999.

**Will rotavirus vaccine prevent most cases of diarrhea?**

Rotavirus vaccine will only prevent diarrhea caused by rotavirus. Rotavirus appears to be responsible for 5–10% of all diarrhea episodes among children less than 5 years of age, however, it is responsible for 30–50% of all severe diarrhea in this age group.

**What is the schedule for rotavirus vaccine?**

Rotavirus vaccine is an oral vaccine given as a three-dose series. The vaccine should be routinely administered at 2, 4, and 6 months of age. The first dose should not be given before 6 weeks of age, and doses may be separated by 3 weeks if an accelerated schedule is needed. The first dose should not be given to children 7 months of age or older because of an increased risk of fever after vaccination in older children. Rotavirus vaccine should not be administered after 12 months of age ever if the series has not been completed.

**Why isn’t rotavirus vaccine given to children over one year of age?**

There are insufficient data on the safety and efficacy of rotavirus vaccine in children 12 months of age and older. The vaccine is not licensed for use after 12 months of age.

**Can I give rotavirus vaccine to an infant who was born preterm?**

Few data are available regarding the safety or efficacy of rotavirus vaccine in premature infants. However, both the ACIP and the AAP recommend vaccination of premature infants if they are at least 6 weeks of age, no longer hospitalized, and clinically stable.

**In whom is rotavirus vaccine contraindicated?**

Rotavirus vaccine should not be given to infants with known or suspected immunodeficiency. Infants whose mothers are infected with HIV should not be given rotavirus vaccine unless laboratory tests have established that the infant is not infected. Rotavirus vaccine should not be given to an infant who has a severe allergy to a vaccine component (aminoglycoside antibiotics, monosodium glutamate, or amphotericin B) or who had...
an anaphylactic reaction to a prior dose of vaccine. Precautions include a moderate or severe acute illness or diarrhea, or pre-existing chronic gastrointestinal disease, such as a malabsorption syndrome, Hirschprung’s disease, or short gut syndrome.

Pregnant or immunodeficient household contacts, recent administration of antibody-containing blood products, and minor acute illness are NOT contraindications to vaccination of a healthy infant.

What are the storage requirements for rotavirus vaccine?
Rotavirus vaccine is supplied as a lyophilized powder, and is reconstituted with 2.5 ml of citrate-bicarbonate buffer. The vaccine and buffer are stable for at least 24 months at room temperatures below 77°F (25°C). If the temperature in your office or clinic exceeds 77°F, the vaccine and buffer should be stored at refrigerator temperature (36-45°F). The vaccine and buffer should not be frozen. Once reconstituted, the vaccine is stable for up to 60 minutes at room temperature (73-81°F) and up to 4 hours at refrigerator temperature.

Lyme disease

by William L. Atkinson, MD, MPH

How serious is Lyme disease?
Lyme disease is the most common insect-transmitted disease in the United States. About 12,000 to 13,000 cases are reported to CDC each year, primarily from states in the northeast, mid-Atlantic, upper midwest, and from northern California. The disease is characterized by a rash, fever, fatigue, and muscle and joint pain. If not adequately treated with antibiotics, Lyme disease may progress to neurologic or rheumatic complications.

Who should receive Lyme disease vaccine?
LYMErix (SmithKline Beecham) is licensed for persons 15–70 years of age. It should not be given to children younger than 15 years of age until approved by the FDA for this age group. Safety and efficacy studies in children are in progress now. Lyme disease vaccine should be considered for persons who reside, work, or recreate in areas of high or moderate risk during Lyme disease transmission season, and who engage in activities that result in frequent or prolonged exposure to tick-infested habitat. The vaccine may be considered for persons in areas of high or moderate risk but whose exposure to tick-infested habitats is neither frequent nor prolonged. An upcoming ACIP statement will include a map to indicate moderate- and high-risk counties. The statement should be published sometime in mid-1999.

What is the dosing schedule for Lyme disease vaccine?
Optimum protection from the vaccine requires 3 doses. The first two doses are given a month apart, and dose #3 is given 12 months after dose #1. Ideally, all 3 doses should be completed one month prior to the anticipated tick-exposure. However, if your patient hasn’t planned a year in advance, dose #1 is recommended 2 months before the anticipated tick-exposure and dose #2 one month later. (Dose #3 should be given 11 months later.)

How effective is Lyme disease vaccine?
Vaccine efficacy of LYMErix against clinical Lyme disease in clinical trials was 49% after two doses and 76% after three doses.

Are booster doses needed every year?
The need for booster doses has not yet been determined. Studies are ongoing.

Rabies

by William L. Atkinson, MD, MPH

An updated ACIP statement on rabies was released in January 1999. What’s new?
“Human Rabies Prevention—United States, 1999,” Recommendations of the Advisory Committee on Immunization Practices, was published in the MMWR on January 8, 1999. The 1999 statement contains new information on the following topics: a human rabies vaccine that was FDA-approved for use in the U.S. in 1997; recommendations regarding exposure to bats; recommendations regarding an observation period for domestic ferrets; and changes in how to administer rabies immune globulin.

Editors’ note: For information on how to obtain this ACIP statement, see page 4.

Who should be offered preexposure rabies vaccination?
Preexposure vaccination should be offered to persons in high-risk groups, such as veterinarians, animal handlers, and certain laboratory workers. Preexposure vaccination also should be considered for other persons whose activities bring them into frequent contact with rabies virus or potentially rabid bats, raccoons, skunks, cats, dogs, or other species at risk for having rabies. In addition, international travelers might be candidates for preexposure vaccination if they are likely to come in contact with animals in areas where dog rabies is enzootic and immediate access to appropriate medical care, including biologics, might be limited.

Influenza

by William L. Atkinson, MD, MPH

Is influenza vaccine recommended for institutionalized or incarcerated youth populations?
Influenza vaccine is not recommended for healthy institutionalized or incarcerated youth. However, institutionalized and incarcerated youth who have underlying illnesses (respiratory, cardiovascular, metabolic, immunosuppression, etc.) should receive annual influenza vaccination.

Should siblings of a patient with a chronic illness receive influenza vaccine even though the patient received the vaccine?
Yes. All household contacts (6 months of age or older) of persons with “high-risk” conditions or persons 65 years of age or older should receive annual influenza vaccination.

In whom is influenza vaccine contraindicated?
Persons who have experienced a severe allergic reaction to a prior dose of influenza vaccine, who are known to have a severe allergy to a vaccine component (such as egg protein) should not be vaccinated. Vaccination should be deferred for a person with moderate or severe acute illness until his/her condition improves. It seems prudent to avoid subsequent influenza vaccine in persons known to have developed Guillain-Barré syndrome within 6 weeks of a previous influenza vaccination.

Pneumococcal

by William L. Atkinson, MD, MPH

How severe is pneumococcal disease?
Pneumococcal infection is estimated to cause up to 40,000 deaths annually in the U.S., accounting for more deaths than any other vaccine-preventable bacterial disease. Approximately half of these deaths potentially could be prevented through the use of vaccine. Case-fatality rates are highest for meningitis and bacteremia, and the highest mortality occurs among the elderly and patients who have underlying medical conditions. Among children, death from pneumococcal infections is relatively uncommon except among those who have meningitis, are immunocompromised, or have undergone splenectomy. Despite appropriate antimicrobial therapy and intensive medical care, the overall case-fatality rate for pneumococcal bacteremia is 15–20% among adults. Among elderly patients, this rate is approximately 30–40%.

My in-laws received pneumococcal vaccine this year and they forgot they had received it later. Have there been problems with repeating this vaccine dose?
Two doses of pneumococcal vaccine this close together could lead to an increase in local reactions, such as pain, redness, or swelling at the site of injection.
Hepatitis B
by Harold Margolis, MD, and Linda Moyer, RN

Should all children 0-18 be vaccinated against hepatitis B?

Yes. In October 1997, the Advisory Committee on Immunization Practices expanded its hepatitis B vaccination recommendations to include all unvaccinated children aged 0-18 years and made hepatitis B vaccine available through the Vaccines for Children program (VFC) for persons age 0-18 years who are eligible for VFC.

We must, however, not forget that our focus should be on routine infant immunization, vaccination of children aged 11-12 who were not routinely vaccinated as infants, high-risk adolescents, and high-risk immigrant and refugee children.

Will vaccinating an infant protect him/her from chronic HBV infection throughout life?

As with all new vaccines, it is currently not known whether infant hepatitis B immunization will confer lifelong immunity against chronic HBV infection, especially adult-acquired infections. A large number of persons vaccinated as infants or young children, and living in populations with high rates of chronic HBV infection, have been followed for up to 15 years, with almost no (<0.1%) late chronic HBV infections. These studies indicate that immune memory persists for a long time and data indicate that boosters of hepatitis B vaccine are not required for at least the first decade following infant, childhood, or adult immunization.

While it is not known whether a booster dose of vaccine will be required to provide lasting immunity for adolescents entering the period of highest risk for HBV infection, follow-up studies are ongoing and should provide this information. The very long incubation period of HBV infection (40–120 days), coupled with the excellent anamnestic antibody response to HBsAg in previously immunized persons, would appear to limit breakthrough infections to ones that do not become persistent.

The Engerix-B package insert states that adolescents aged 11–19 years can receive either 10 mcg or 20 mcg of this vaccine. Everything I have read, however, states 10 mcg is the recommended dose. What should I do?

The FDA has licensed the 10 mcg dosage of Engerix B vaccine for adolescents. The ACIP recommendations for the use of Engerix-B vaccine state that all children 0–19 years of age should be given 10 mcg per dose (MMWR 1996; 45[RR-13]:5).

I work in a dialysis unit. Our lab reports anti-HBs results as adequate or inadequate, rather than providing a quantitative result. Is this acceptable?

Reporting of adequate and inadequate is acceptable only if your lab is using mIU as the measurement for anti-HBs and the cutoff is below 10 for reporting inadequate anti-HBs and 10 or above for reporting adequate anti-HBs. You should check with your lab to be certain this is being done.

For a pre-employment physical, a health care worker states she received all three hepatitis B vaccine doses as an adolescent. Would you do a titer?

This is a situation that will become more common in the future and for which there are no specific guidelines. A reasonable approach, however, can be developed from current recommendations. Currently, CDC recommends postvaccination testing for antibody to hepatitis B surface antigen (anti-HBs) 1–2 months after the last dose of hepatitis B vaccine for persons vaccinated as health care workers or in training. This employee was vaccinated as an adolescent, and postvaccination testing was not done since it was not indicated at the time of vaccination.

If the health care worker has written documentation of three doses of vaccine given as an adolescent, that should be sufficient to meet the needs of the employer and the requirements of OSHA guidelines. Another option would be to test the person for the presence of anti-HBs, since a person vaccinated as an adolescent is still likely to have detectable antibody. If the person, however, is anti-HBs negative on testing, that does not mean s/he was not immunized, since s/he could have lost detectable antibody over time and still be protected. If the person is found to be anti-HBs negative, that status should be recorded on her/his employee health record along with the vaccination history. If the health care worker subsequently has a blood exposure, s/he should follow the current guidelines for postexposure immunoprophylaxis. If the health care worker has no written documentation of vaccination as an adolescent, the person should receive the 3-dose vaccine series and anti-HBs testing 1–2 months after the full series.

A person who is a “known non-responder” to hepatitis B vaccine has a percutaneous exposure to HBsAg positive blood. According to the ACIP recommendations, I have the option to give hepatitis B immune globulin (HBIG) x 2 or HBIG x 1 and initiate revaccination. How do I decide which to do?

If the person is a true “non-responder” (i.e., failed to produce adequate anti-HBs after two full vaccine series), it seems illogical to give a third hepatitis B vaccine series. The two-dose HBIG regimen would be the better choice. The first dose of HBIG (0.06ml/kg) should be given as soon as possible after exposure and the second dose (same dosage) given one month later. If the person has failed only one hepatitis B vaccine series, the second option (HBIG x 1 and initiate revaccination) should be used. Postvaccination testing with anti-HBs should be done 1–2 months after the second series of vaccine.

I oversee the employees of a clinic in which all the health care workers decided to check their anti-HBs titers (15 employees got tested). Eight of them had titers less than 10 mIU/ml, although two of them had previously had adequate titers. The other seven had not been previously tested. What should I do?

CDC does not recommend periodic testing for anti-HBs or booster doses of hepatitis B vaccine for immune competent persons. When testing is done as described above, it places the employee health service in a difficult position. The two employees who previously had documented adequate titers should have nothing done as they are protected. It also appears that 7 of the 15 employees had adequate levels of anti-HBs when tested. That leaves 6 employees in which it is not known if they had previously responded to hepatitis B vaccination and now have undetectable anti-HBs.

The most helpful approach to define the issue, would be to give one dose of vaccine to each of the employees and then test anti-HBs in one month. For employees with adequate anti-HBs (≥10mIU/ml), nothing more need be done, as they are protected. For employees with inadequate anti-HBs after one additional dose of vaccine, we would complete the revaccination series by giving two.
more doses of vaccine according to the recommended schedule and test 1–2 months after the third dose of vaccine. If anti-HBs is adequate, they are protected; if inadequate, they are “non-responders” to the vaccine.

How many days after a percutaneous exposure can HBIG be given? Our lab doesn’t provide blood results until 7 days after the blood is drawn. Should we wait to give HBIG, or should we go ahead with HBIG and hepatitis B vaccine?
If you must wait on testing to determine the patient’s HBsAg status, vaccine should be started immediately while awaiting test results. HBIG can then be given within 7 days if the patient is HBsAg-positive. Considering the type of tests that are available today, laboratories should be capable of reporting results back to you within 7 days. We would not give HBIG farther out than 7 days from an exposure to HBsAg-positive blood. The hepatitis B vaccine series, however, should be completed and would alone offer good protection.

If the health care worker had been vaccinated and had developed adequate anti-HBs, this would not be an issue. If the exposure is to known HBsAg-positive blood and the health care worker was not vaccinated, a single dose of HBIG (0.06mL/Kg) should be given as soon as possible after exposure (within 24 hours, if possible). The first dose of hepatitis B vaccine should be administered at a different site, but at the same time as the HBIG. The vaccine series should be completed according to current recommendations.

I have chronic HBV and am HBsAg-positive with normal liver functions. I am expecting my first baby and my doctor says that because I am HBsAg-positive, I should not breast-feed. Do you agree?
No, we do not agree. Babies who have HBIG and hepatitis B vaccine given in a timely fashion at birth can be breast-fed, even by mothers who are HBsAg-positive. Prior to hepatitis B vaccine and HBIG availability, studies found no transmission from HBsAg-positive mothers to their breast-fed babies.

Babies born to HBsAg-positive mothers should receive their first dose of hepatitis B vaccine and HBIG within 12 hours of birth; the second dose of vaccine at age 1–2 months; and the third dose of vaccine at age 6 months. Babies should be tested for HBsAg and anti-HBs at age 9–15 months to determine success or failure of immunoprophylaxis.

Which adults are at the highest risk of HBV infection?
Most HBV infections in adults occur among persons who have defined risk factors for HBV infection, including persons with multiple sex partners (more than one partner during the preceding 6 months); men who have sex with men; persons who have a sexually transmitted disease (STD) or who have ever had an STD; sex partners and household contacts of persons who have chronic HBV infection; patients in hemodialysis units; recipients of certain blood products; illicit inject-drug users; health care workers and public safety workers who are exposed to blood; clients and staff of institutions for the developmentally disabled; persons who are incarcerated; and certain international travelers.

Hepatitis A
by Harold Margolis, MD, and Linda Moyer, RN

Is it true that children who live in certain states, counties, and/or communities in the U.S. need hepatitis A vaccine?
Yes. Routine vaccination of children is recommended in states where the average annual hepatitis A rate during 1987–97 was at least 20/100,000 population (i.e., approximately 2 times the national average). These states are Alaska, Arizona, California, Idaho, Nevada, New Mexico, Oklahoma, Oregon, South Dakota, Utah, and Washington.

Routine vaccination of children is also recommended in counties and/or communities where the average annual hepatitis A rate during 1987–97 was at least 20/100,000 population (i.e., approximately 2 times the national average).

Routine hepatitis A vaccination of children may be considered in states where the average annual hepatitis A rate during 1987–97 was at least 10/100,000 population but less than 20/100,000. These states are Arkansas, Colorado, Missouri, Montana, Texas, and Wyoming.

Routine hepatitis A vaccination of children may also be considered in counties and/or communities where the average annual hepatitis A rate during 1987–97 was at least 10/100,000 population but less than 20/100,000.

Possible strategies for childhood vaccination include vaccinating one or more single age cohorts of children (e.g., children at the age of entry into pre-school, elementary school, and/or middle school), vaccination of children in selected settings (e.g., daycare entry), or vaccination of children over a wider range of ages in a variety of settings, such as when they seek health care for other purposes.

I have a patient on interferon for hepatitis C, but I want to give him hepatitis A and hepatitis B vaccines. Is it okay to vaccinate him against hepatitis A and B while he is on interferon?
Patients with chronic liver disease are at increased risk for adverse outcomes if they acquire hepatitis A virus (HAV) infection. Therefore, hepatitis A vaccine should be given to all susceptible patients with chronic liver disease. Hepatitis A vaccine is very immunogenic and the patient’s diminished immune status due to interferon should not affect the immunogenicity and effectiveness of the vaccine, although there are no data to support that statement. Studies still need to be done to address this issue. Current assays are generally not adequate for hepatitis A postvaccination testing as protective levels of antibody produced by vaccination may be at a level that the test cannot detect. Clearly, if antibody testing is done and the result is positive in a vaccinated patient, that patient is protected.

If the patient is in a group for whom hepatitis B vaccine is recommended, interferon treatment should not preclude hepatitis B vaccination. Postvaccination testing, however, should be done 1–2 months after the last dose of hepatitis B vaccine to assure adequate protection.

I provide travel immunizations to persons who go on extended international leave. Will 1 dose of hepatitis A vaccine protect a person who is unable to receive the second dose at the recommended 6–18 month interval?
Hepatitis A vaccine is very immunogenic; however, there are no data that examine long-term immunogenicity after just one dose of vaccine. Since hepatitis A vaccine is so immunogenic, it is reasonable to not repeat the first vaccine dose, but to give the second dose whenever the person returns from travel/leave. Another option would be for the traveler to consider taking the second dose of hepatitis A vaccine with him/her and having it administered with a sterile syringe and proper technique at the recommended 6–18 month interval in the country to which he/she is traveling.

My patient required IG immunoprophylaxis because of exposure to HAV. Should I have started the hepatitis A vaccine series as well?
Only if your patient is in a group for whom hepatitis A vaccine is routinely recommended. In addition, if your patient lives in a state, county, or community in which routine hepatitis A vaccination should be considered or is recommended (see prior question), giving IG for postexposure immunoprophylaxis represents an opportunity to also begin the hepatitis A vaccine series.

Why does a duck need some money come out of the water?
Organizations with immunization and hepatitis information

Routine Immunization
- All Kids Count (www.allkidscount.org) national registry conference 4/28–29 404-687-5615
- American Academy of Pediatrics (www.aap.org) ★ 800-433-9016
- Association of Teachers of Preventive Medicine (www.atpm.org) 800-789-6737
- CDC’s Immunization Information Hotline 800-232-2522
- CDC’s Voice and Fax Immunization Information Line 888-232-3228
- CDC’s Nat’l Immunization Program website www.cdc.gov/nip/
- CDC’s Vaccine Safety website www.cdc.gov/nip/vacsafe/
- CDC’s Vaccines For Children website www.cdc.gov/nip/vfc/
- CDC’s Immunization Registry website www.cdc.gov/nip/reginfo/
- CDC’s Travel website www.cdc.gov/travel/
- Congress of Nat’l Black Churches 202-371-1091
- COSSMHO (Nat’l Coalition of Hispanic Health Orgs.) (www.cossmho.org) ★ 202-387-5000
- Every Child by Two (www.ecbt.org) 202-783-7034
- Immunization Action Coalition (www.immunize.org) ★ 651-647-9009
- Immunization Education and Action Committee (www.hmmh.org) 703-836-6110
- Immunization Gateway website www.immunofacts.com
- Nat’l Council of La Raza (www.nclr.org) ★ 202-785-1670
- Nat’l Vaccine Injury Compensation Program (www.hrsa.dhhs.gov/bhpr/vicp/) 800-338-2382
- Roll Up BOTH Sleeves (a manual on how to vaccinate in middle schools) 330-678-1601
- Sabin Vaccine Institute (www.sabin.georgetown.edu) 202-687-9145
- Vaccine Adverse Events Reporting System (www.fda.gov/cber/vaers/vaers.html) 800-822-7967
- Vaccine Page (for the latest vaccine news, etc., on the web) www.vaccines.com
- Your health department’s immunization program manager (see next page) …

Hepatitis Information
- American Liver Foundation (www.liverfoundation.org) ★ 800-223-0179
- CDC’s Hepatitis Information Hotline ★ 888-443-7232
- CDC’s Hepatitis website www.cdc.gov/ncidod/diseases/hepatitis/hepatitis.htm
- Hepatitis B Coalition (www.immunize.org) ★ 651-647-9009
- Hepatitis B Foundation (www.hepb.org) ★ 215-489-4900
- Hepatitis B On-Line Support Group … send a blank e-mail to: hepatitis-b-on@mail-list.com
- Hepatitis Control Report (www.hepatitiscontrolreport.com) 610-664-2793
- Hepatitis Foundation International (www.hepfi.org) ★ 800-891-0707
- Nat’l Task Force on Hepatitis B: Focus on APIA (www.aapihep.org/hepbf/) ★ 614-766-5219
- Parents of Kids with Infectious Diseases (www.pkids.org) 360-695-0293
- PEPLine: 24-hr hotline to advise clinicians re: occupational blood exposures 888-448-4911
- Plexus Health Group (consultants for hepatitis B community projects) 912-638-6705
- Your health department’s hepatitis coordinator (see next page) …

Pharmaceutical Companies
- Aviron (www.aviron.com) 650-919-6500
- Chiron Corporation (www.chiron.com) 800-244-7668
- Merck & Co., Inc. (www.merck.com) 800-672-6372
- North American Vaccine (www.nava.com) 410-309-7100
- Pasteur Merieux Connaught, Inc. (www.us.pmc-vacc.com) 800-822-2463
- SmithKline Beecham (www.sb.com) 800-366-8900
- Wyeth-Lederle Vaccines & Pediatrics (www.ahp.com) 800-358-7443
- Your health department’s hepatitis coordinator (see next page) …

★ materials available in other languages as well as English
Need Help?

**Call your immunization, hepatitis, and VFC coordinators**

Get to know your governmental resource people. They are there to help you! Find out what kind of patient and provider educational materials they have including posters, brochures, and videos. Call them to register for the excellent immunization conferences that CDC broadcasts by satellite. They may also be able to help you audit your clinic’s immunization rates and/or help you develop immunization tracking systems. Give them a call!

### State Coordinators

<table>
<thead>
<tr>
<th>State</th>
<th>Hep B: Name</th>
<th>Hep B: Phone Number</th>
<th>Iz: Name</th>
<th>Iz: Phone Number</th>
<th>VFC: Name</th>
<th>VFC: Phone Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arizona</td>
<td>Kathleen Russell</td>
<td>302-739-4746</td>
<td>Charles Miller</td>
<td>808-586-8311</td>
<td></td>
<td></td>
</tr>
<tr>
<td>California</td>
<td>Natalie Smith</td>
<td>510-540-2065</td>
<td>Les Burd</td>
<td>510-540-2879</td>
<td>John Scott</td>
<td>510-704-3750</td>
</tr>
<tr>
<td>Colorado</td>
<td>Gary Jones</td>
<td>510-661-2170</td>
<td>Natalie Smith, MD</td>
<td>510-540-2065</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Connecticut</td>
<td>Vincent Sacco</td>
<td>800-509-7929</td>
<td>Mitsu Sug</td>
<td>808-586-8383</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Delaware</td>
<td>Aaron Roome</td>
<td>860-509-7900</td>
<td>John Scott</td>
<td>510-704-3750</td>
<td></td>
<td></td>
</tr>
<tr>
<td>District of Columbia</td>
<td></td>
<td></td>
<td>Charles Miller</td>
<td>808-586-8311</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Florida</td>
<td>Gary Warner</td>
<td>303-692-2669</td>
<td>Ruby Jones</td>
<td>510-661-2170</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Georgia</td>
<td>Michael Cheney</td>
<td>404-657-3158</td>
<td>Peggy Monkos</td>
<td>404-657-3158</td>
<td>Stephanie Boatenreiter</td>
<td>404-657-3158</td>
</tr>
<tr>
<td>Hawaii</td>
<td>Lin Watson</td>
<td>808-586-8330</td>
<td>Charles Miller</td>
<td>808-586-8311</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Idaho</td>
<td>Merlene Fletcher</td>
<td>208-334-5942</td>
<td>Bob Salisbury</td>
<td>208-334-4949</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Indiana</td>
<td>Cheryl Byers</td>
<td>317-746-6120</td>
<td>Monty Dobzyn</td>
<td>317-746-7147</td>
<td>John Scott</td>
<td>510-704-3750</td>
</tr>
<tr>
<td>Iowa</td>
<td>Dave Ellsworth</td>
<td>317-233-7010</td>
<td>Thomas Hicks</td>
<td>217-785-1455</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kansas</td>
<td>Mona Vysocki</td>
<td>217-785-1455</td>
<td>Martha Siemsen</td>
<td>785-296-2774</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kentucky</td>
<td>Sandra Gambescia</td>
<td>502-564-4478</td>
<td>Ruby Jones</td>
<td>510-661-2170</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Louisiana</td>
<td>Reuben Tapia</td>
<td>504-483-1900</td>
<td>Cathy Scott</td>
<td>318-345-1700</td>
<td>Patricia Simon</td>
<td>504-483-1900</td>
</tr>
<tr>
<td>Maine</td>
<td>Jude Walsh</td>
<td>207-287-3746</td>
<td>Jude Walsh</td>
<td>207-287-3746</td>
<td>Linda Huff</td>
<td>207-287-3746</td>
</tr>
<tr>
<td>Maryland</td>
<td>Mark Amerson</td>
<td>217-785-1455</td>
<td>Susan Williams</td>
<td>217-785-1455</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Massachusetts</td>
<td>Bob Goldstein</td>
<td>617-983-6800</td>
<td>Linda Keller</td>
<td>617-983-6800</td>
<td>Peggy Parnell</td>
<td>785-296-6800</td>
</tr>
<tr>
<td>Michigan</td>
<td>Dr. Gillian Stoltman</td>
<td>517-335-8159</td>
<td>Nancy Fasoan</td>
<td>517-335-8159</td>
<td>Susan Weight</td>
<td>517-335-8159</td>
</tr>
<tr>
<td>Minnesota</td>
<td>Alan Lifson</td>
<td>612-676-5237</td>
<td>Margo Roddy</td>
<td>612-676-5237</td>
<td>Barbara Ottis</td>
<td>612-676-5237</td>
</tr>
<tr>
<td>Missouri</td>
<td>Vic Tomlinson</td>
<td>573-751-6133</td>
<td>Ruby McPherson</td>
<td>600-699-2313</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Montana</td>
<td>Joyce Burgett, RN</td>
<td>406-444-0065</td>
<td>Marci Ekeren</td>
<td>406-444-1805</td>
<td>Elizabeth Evans</td>
<td>406-444-0277</td>
</tr>
<tr>
<td>New Hampshire</td>
<td>Lisa Hostler</td>
<td>505-827-2465</td>
<td>Lisa Hostler</td>
<td>505-827-2465</td>
<td>Roger Brumley</td>
<td>505-827-2899</td>
</tr>
<tr>
<td>New Mexico</td>
<td>Lisa Hostler</td>
<td>505-827-2465</td>
<td>Lisa Hostler</td>
<td>505-827-2465</td>
<td></td>
<td></td>
</tr>
<tr>
<td>New York City</td>
<td>Arsenia Delgado</td>
<td>212-676-2259</td>
<td>Davis Thanjan</td>
<td>718-520-8245</td>
<td>Dileep Sarecha</td>
<td>212-676-2298</td>
</tr>
<tr>
<td>North Carolina</td>
<td>Beth Rowe-West</td>
<td>919-715-6777</td>
<td>Lisa Hostler</td>
<td>505-827-2465</td>
<td></td>
<td></td>
</tr>
<tr>
<td>North Dakota</td>
<td>Patrick Flanagan</td>
<td>701-328-4556</td>
<td>Patrick Flanagan</td>
<td>701-328-4556</td>
<td>Patrick Flanagan</td>
<td>701-328-4556</td>
</tr>
<tr>
<td>Ohio</td>
<td>Joseph Bronowski</td>
<td>614-466-4643</td>
<td>Joseph Bronowski</td>
<td>614-466-4643</td>
<td>Mark Keeler</td>
<td>614-752-1361</td>
</tr>
<tr>
<td>Oklahoma</td>
<td>Don Blose</td>
<td>405-271-4073</td>
<td>Leonard Lang</td>
<td>405-271-4073</td>
<td>Dorothy Cox</td>
<td>405-271-4073</td>
</tr>
<tr>
<td>Oregon</td>
<td>Lorraine Duncan</td>
<td>503-731-4135</td>
<td>Amanda Timmons</td>
<td>503-731-4564</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pennsylvania</td>
<td>Alice Gray</td>
<td>717-787-5681</td>
<td>Joseph Bronowski</td>
<td>614-466-4643</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pennsylvania</td>
<td>Phoebe Tran</td>
<td>717-787-5681</td>
<td>Vickie Petrin</td>
<td>717-787-5681</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Territories

[continued on next page]
NEEDLE TIPS

Coalition Catalog
Publications and resources

- All of our materials are camera ready, copyright free, and reviewed by national experts!
- You can order just one of any item and make as many copies as you need (including videos).
- Each item costs $1 (unless otherwise stated).
- Starred items are available in foreign languages.
- To order materials, see instructions on page 26.
- Join the Coalition for 1999 with a $50 membership and we will send you ALL of our print materials. See the order form for details on page 27.
- We accept credit cards.

Before you order, REMEMBER...
A $50 annual membership brings you camera-ready copies of ALL of the Coalition’s print materials. See the order form or the back page for information on how to join!

Brochures for your patients

Revised! Immunizations for babies. A picture of the shot schedule (3/99). Item #P4010

★ After the shots...what to do if your child has discomfort. English, Spanish, Cambodian, Chinese, Farsi, Hmong, Korean, Laotian, Russian, Tagalog, Vietnamese (2/97). Item #P4015

Are you 11–19 years old? Then you need to be vaccinated! Covers all vaccinations for teenagers (4/98). Item #P4020

Revised! Questions parents ask about baby shots. A brochure about childhood vaccinations (3/99). Item #P4025

Vaccinations for adults—you’re never too old for shots! A visual table covering all adult vaccinations (10/97). Item #P4030

★ Immunizations...not just kids’ stuff. Adult immunization brochure. English, Spanish, Chinese (2/97). Item #P4035

Shots for adults with HIV. A visual table of shots needed for HIV-positive adults (7/97). Item #P4041

Vaccinations for adults with hepatitis C. This one-page sheet describes vaccinations that HCV-positive adults need (10/98). Item #P4042


★ Chickenpox isn’t just an itchy, contagious rash. A brochure for all ages. English, Spanish (12/95). Item #P4070

★ Hepatitis A is a serious disease... should you be vaccinated? A brochure for all ages. English, Spanish (10/97). Item #P4080

★ Questions frequently asked about hepatitis B. Four pages of commonly asked questions. English, Spanish (9/96). Item #P4090

★ Every week hundreds of teens are infected with hepatitis B. A brochure for teens and parents. English, Spanish, Cambodian, Chinese, Hmong, Korean, Laotian, Russian, Tagalog, Vietnamese (5/97). Item #P4100

★ Hepatitis B shots recommended for all new babies. A brochure for parents of newborns. English, Spanish, Cambodian, Chinese, Hmong, Korean, Laotian, Russian, Vietnamese (1/96). Item #P4110

★ Every week thousands of sexually active people get hepatitis B. A hepatitis B brochure for adults. English and Spanish (4/98). Item #P4112

NEW! If you have sex, read this...and stop a killer STD from sneaking up on you (reprinted from Mademoiselle, 2/99). Use this article to help convince young women to get vaccinated against hepatitis B. Item #P4113

Hepatitis B . . . 100 times easier to catch than HIV. A brochure for men who have sex with men (2/97). Item #P4115

You don’t have to go all the way to get hepatitis A. A brochure for men who have sex with men (7/97). Item #P4116

You are not alone! Article for teens with chronic HBV infection. By S.J. Schwarzenberg, MD, U of MN; and K. Wainwright, RN, Alaska Area Native Health Service, Anchorage (10/98). Item #P4118

★ If you are a hepatitis B carrier... How hepatitis B carriers can take care of themselves and protect others. English, Spanish, Chinese, Hmong (12/95). Item #P4120

Packet of hepatitis B adoption information. Includes information from adoption specialists throughout the U.S. Item #P4152 - $5

★ Hepatitis B information for adults and children from endemic areas. Encourages testing and vaccination. English, Cambodian, Chinese, Hmong, Korean, Laotian, Russian, Tagalog, Vietnamese. Item #P4170

Materials for your clinic staff


Summary of recommendations for adult immunization. A two-sided reference table on appropriate use, scheduling, and contraindications of vaccines (10/98). Item #P2011

Pneumococcal vaccine: who needs it and who needs it again. A one-page Q and A with a table about revaccination (4/98). Item #P2015

FREE MATERIALS! All of our print items are available free on our website at www.immunize.org
Vaccine handling, storage, and transport. (9/96). Item #P2020


Revised! Vaccine administration record for children and teens. Keep children and teens’ immunization records on this one-page sheet in the front of their medical charts (3/99). Item #P2022

Vaccine administration record for adults. Keep adult patients’ immunization records on this one-page sheet in the front of their medical charts (8/98). Item #P2023

NEW! It’s federal law! You must give your patients current Vaccine Information Statements (VISs) (by Neal A. Halsey, MD, Institute for Vaccine Safety, Johns Hopkins School of Public Health). Everything you NEED to know about VISs (10/98). Item #P2027

Tips to improve your clinic’s immunization rates. For use in both pediatric and adult health settings (2/97). Item #P2045

NEW! Vaccinate, don’t vaccilate! Varicella kills 100 people each year in the U.S. What are you waiting for? (by Walter A. Orenstein, MD, Ass’t Surgeon General, Director, NIP, CDC). If you aren’t yet convinced that it’s important to vaccinate for varicella, read this! (10/98) Item #P2058

Hospitals & doctors sued for failing to immunize. Seven lawsuits against physicians and hospitals (12/94). Item #P2060

Recommended child and adult dosages of the two brands of hepatitis A and B vaccines (10/98). Item #P2081

No risk?? No way!! Reviews unusual transmissions of hepatitis B in “low-risk” individuals (9/94). Item #P2100

Hepatitis B and the health care worker. How to protect health care workers, includes post-exposure prophylaxis guidelines (4/98). Item #P2109

Revised! Basic knowledge about hepatitis B. A list of high-risk groups, interpretation of the hepatitis B panel, and tests to diagnose chronic hepatitis B, C, and D (3/99). Item #P2110

Revised! Basic facts about adult hepatitis B. A list of adult high-risk groups, interpretation of the hepatitis B panel, and tests to diagnose chronic hepatitis B, C, and D (3/99). Item #P2112

Universal prenatal screening for hepatitis B (by D. Freese, MD, Mayo Clinic, Rochester, MN). Reviews neonatal transmission and screening rationale (2/93). Item #P2120

Sample hospital perinatal protocols. For HBsAg screening on labor and delivery units and hepatitis B immunization in newborn nurseries (12/95). Item #P2130

Revised! Does your patient have chronic hepatitis B? (by C. Smith, MD, Minnesota Gastroenterology, Minneapolis, MN). One-page Q and A plus table on HBV markers and their significance (3/99). Item #P2162

Management of chronic hepatitis B in children and/or adults. Four liver experts share their management guidelines for chronic hepatitis B. Authored by H. Conjeevaram, MD, University of Chicago, IL (1/97); C. Smith, MD, Minnesota Gastroenterology, Minneapolis, MN (1/97); B.J. McMahon, MD, Alaska Area Native Health Service, Anchorage, AK (12/95); S.J. Schwarzenberg, MD, University of MN (8/94). Item #P2164 - $5

Tracking hepatitis B patients and household contacts. Manual tracking system for high-risk families (10/98). Item #P2180

Kid art. Immunization artwork (bribes, bears, balloons, etc.) you can use to make your own brochures, posters, etc. (9/96). Item #P3015 - $5


★ Screening questionnaire for child and teen immunization. A form for the patient’s parent/guardian to fill out to help staff evaluate which vaccines can be given at that day’s visit (12/95). English, Spanish, Chinese, Hmong. Item #P4060

★ Screening questionnaire for adult immunization. A form your adult patients fill out to help you evaluate which vaccines can be given at that day’s visit. English, Spanish (2/97). Item #P4065

Sample letter explaining hepatitis B test results to patients (10/97).

Vaccines for your clinic staff

How to Protect Your Vaccine Supply (Ice, Champagne, and Roses) (CA Dept. of Health, MN Dept. of Health, 1996, 15 min). This “how-to” video also covers varicella and hepatitis A vaccines. Comes with accompanying print material. Item #V2010 - $10

Vaccine Administration Techniques (CA Dept. of Health, 1989, 18 min). A refresher course on the correct techniques for administering vaccines. Comes with accompanying print material. Item #V2020 - $10

When to Immunize, When to Wait (CA Dept. of Health, 1995, 22 min). Features CDC’s immunization expert, Dr. William Atkinson. Includes accompanying print materials. Item #V2030 - $10

In Praise of the Public Health Nurse! (IAC, 1994, 31 min). Features Margaret Morrison, MD, MS Dept. of Health, who stresses that immunization is a team effort. Comes with print material. Item #V2040 - $10

Videos for teens and pre-teens


Partnership for Prevention (SKB, 1995, 6 min). A hepatitis B video for 11– and 12–year olds. May not be broadcast on television. Item #V3012 - $10

Get the Facts, Then Get the Vax (ASHA, 1995, 6 min). A hepatitis B video for high school students. Item #V3015 - $10

Resources for Asians and Pacific Islanders

Contact us! We have resources to help you conduct immunization and/or hepatitis B campaigns in Asian and Pacific Islander communities. We have resource manuals, videos (in English, Cambodian, Hmong, Laotian, Vietnamese, and Mien) and materials to train bilingual workers (videos, slides, training manuals, and more). Each item is only $10! Fax your request for our “API Resource List/Order Form” to 651/647-9131 or call 651/647-9009 for more information.

(continued on page 26)
Photos, slides, posters, and more

**Teen poster!** Roll up your sleeves! Full-color 11” x 17” poster of a diverse trio of kids showing off their hepatitis B shots! Item #Q2010 - 10 posters for $1 (order in units of 10)

**Adult poster!** Immunization...not just kids’ stuff. A two-color 7” x 14” adult poster. Hang this poster up in every exam room. Item #Q2020 - 10 posters for $1 (order in units of 10). The companion brochure is item #P4035.


**Photo notebook of vaccine-preventable diseases.** Includes 20 full-page color photos of children and adults with vaccine-preventable diseases and simple text that describes the diseases. Perfect for taking out into the community to give presentations. Outreach workers love it! (9/97). Item #R2053 - $75

**NEW! Unprotected People: Stories of people who have suffered or died from vaccine-preventable diseases.** First-person stories, case reports, and newspaper articles that illustrate the tragedies that occurred because someone wasn’t immunized. All of these stories previously appeared in IAC EXPRESS and/or NEEDLE TIPS (8/98–1/99). Item #R2057 - $5

**Vaccine-preventable diseases slide set and script.** Includes 30 slides of children and adults with vaccine-preventable diseases. Suitable for use by public health departments, community outreach workers, nursing schools, and medical teaching programs. Comes with English and/or Spanish scripts. Every clinic should have a set of these slides (9/96). Item #S3010 - $25

Unprotected People

Stories of people who died or suffered from vaccine-preventable diseases

First-person stories, case reports, and newspaper articles that illustrate the tragedies that occurred because someone wasn’t immunized. All of these stories previously appeared in IAC EXPRESS and/or NEEDLE TIPS (8/98–1/99). Item #R2057 - $5

**Sign up for IAC EXPRESS!** Sign up for IAC EXPRESS! and the Immunization Action Coalition will keep sending you these stories and other timely immunization information directly to your e-mail box. To subscribe: send an e-mail to express@immunize.org and place the word SUBSCRIBE in the Subject field. It’s free!

STOP

READ THIS BEFORE YOU ORDER!

Join the Coalition for 1999! With a $50 membership, we will send you a complete package of all our print materials in the languages you specify.

Ordering Information

- All of our materials are camera ready, copyright free, and reviewed by national experts!
- You can order just one of any item and make as many copies as you need (including our videos).
- Minimum order/donation $10, please.
- We request prepayment by check or credit card. Purchase orders accepted.
- You may fax us your credit card order or your purchase order.
- Checks must be in U.S. dollars.
- Make sure the order form accompanies your order.
- Orders are shipped via fourth class mail. No charge for shipping and handling within the U.S.
- Expect delivery in approximately 3 weeks.

Robin, did you send our membership donation to the Immunization Action Coalition?

Leapin Lizards, Batman! Why do you think that huge pack of print materials is on your desk??
Coalition Order Form

Payment, Shipping, and Handling Information
Minimum order/donation $10. We request prepayment by check or credit card. Purchase orders accepted. Checks in U.S. dollars. Order form must accompany check or PO. (Our Federal ID# is 41-1768237). Orders shipped via fourth class mail. No charge for shipping within the U.S. Expect delivery in three weeks.

Immunization Action Coalition & Hepatitis B Coalition
1573 Selby Avenue, Suite 234, St. Paul, MN 55104
Phone 651/647-9009 • Fax 651/647-9131

Before you order, remember: A $50 annual membership includes camera-ready copies of ALL of the Coalition's print materials.

Languages

<table>
<thead>
<tr>
<th>English</th>
<th>Spanish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ar: Armenian</td>
<td>Hm: Hmong</td>
</tr>
<tr>
<td>Ca: Cambodian</td>
<td>J: Japanese</td>
</tr>
<tr>
<td>Ch: Chinese</td>
<td>K: Korean</td>
</tr>
<tr>
<td>Fa: Farsi</td>
<td>La: Laotian</td>
</tr>
<tr>
<td>Po: Portuguese</td>
<td>Sa: Samoan</td>
</tr>
<tr>
<td>R: Romanian</td>
<td>Ta: Tagalog</td>
</tr>
<tr>
<td>Ru: Russian</td>
<td>Vi: Vietnamese</td>
</tr>
</tbody>
</table>

Before you order, remember:

Name/Title
Organization
Shipping address
State Zip Telephone
Mailcode E-mail address

(online above name on your mailing label)

Qty. Amt.

<table>
<thead>
<tr>
<th>Qty.</th>
<th>Amt.</th>
</tr>
</thead>
<tbody>
<tr>
<td>P4010</td>
<td>Immunizations for babies</td>
</tr>
<tr>
<td>P4015</td>
<td>After the shots: what to do if your child has discomfort:</td>
</tr>
<tr>
<td>P4020</td>
<td>Are you 11-19? Then you need to be vaccinated!</td>
</tr>
<tr>
<td>P4025</td>
<td>Questions parents ask about baby shots</td>
</tr>
<tr>
<td>P4030</td>
<td>Vaccinations for adults</td>
</tr>
<tr>
<td>P4035</td>
<td>Immunizations...not just kids stuff:</td>
</tr>
<tr>
<td>P4041</td>
<td>Shots for adults with HIV</td>
</tr>
<tr>
<td>P4042</td>
<td>Vaccinations for adults with hepatitis C</td>
</tr>
<tr>
<td>P4050</td>
<td>When do children and teens need shots:</td>
</tr>
<tr>
<td>P4055</td>
<td>All kids need hepatitis B shots:</td>
</tr>
<tr>
<td>P4070</td>
<td>Chickenpox isn't just an itchy, contagious rash:</td>
</tr>
<tr>
<td>P4080</td>
<td>Hepatitis A is a serious disease, should you be vaccinated?</td>
</tr>
<tr>
<td>P4090</td>
<td>Questions frequently asked about hepatitis B:</td>
</tr>
<tr>
<td>P4100</td>
<td>Every week hundreds of teens are infected with hepatitis B:</td>
</tr>
<tr>
<td>P4110</td>
<td>Hepatitis B shots recommended for all new babies:</td>
</tr>
<tr>
<td>P4112</td>
<td>Every week thousands of sexually active people get hepatitis B:</td>
</tr>
<tr>
<td>P4113</td>
<td>If you have sex, read this</td>
</tr>
<tr>
<td>P4115</td>
<td>Hepatitis B is 100 times easier to catch than HIV</td>
</tr>
<tr>
<td>P4116</td>
<td>You don't have to go all the way to get hepatitis A</td>
</tr>
<tr>
<td>P4118</td>
<td>You are not alone: teens with hepatitis B</td>
</tr>
<tr>
<td>P4120</td>
<td>If you are a hepatitis B carrier:</td>
</tr>
<tr>
<td>P4152</td>
<td>Packet of hepatitis B and adoption information</td>
</tr>
<tr>
<td>P4170</td>
<td>Hep B information for adults &amp; children from endemic areas:</td>
</tr>
</tbody>
</table>

Materials for your clinic staff

<table>
<thead>
<tr>
<th>Qty.</th>
<th>Amt.</th>
</tr>
</thead>
<tbody>
<tr>
<td>P2010</td>
<td>Summary of rules for childhood immunization</td>
</tr>
<tr>
<td>P2011</td>
<td>Summary of recommendations for adult immunization</td>
</tr>
<tr>
<td>P2015</td>
<td>Pneumococcal vaccine: who needs it, who needs it again?</td>
</tr>
<tr>
<td>P2020</td>
<td>Vaccine handling, storage, and transport</td>
</tr>
<tr>
<td>P2021</td>
<td>Ask the experts</td>
</tr>
<tr>
<td>P2022</td>
<td>Vaccine administration record for children and teens</td>
</tr>
<tr>
<td>P2023</td>
<td>Vaccine administration record for adults</td>
</tr>
<tr>
<td>P2027</td>
<td>It's federal law! You must give VIs</td>
</tr>
<tr>
<td>P2045</td>
<td>Tips to improve your clinic's immunization rates</td>
</tr>
<tr>
<td>P2100</td>
<td>No risk? No way!</td>
</tr>
<tr>
<td>P2109</td>
<td>Hepatitis B and the health care worker</td>
</tr>
<tr>
<td>P2110</td>
<td>Basic knowledge about hepatitis B</td>
</tr>
<tr>
<td>P2112</td>
<td>Basic facts about adult hepatitis B</td>
</tr>
</tbody>
</table>

Please join the Coalition!
This is the total amount for the materials I'm ordering. $ __________
I appreciate NEEDLE TIPS. Here's my contribution to help defray costs ($25 suggested) $ __________
I want to join the Coalition for 1999
❑ I am a new member
❑ I am a renewing member

Here is my 1999 membership contribution
❑ $50 $75 $90 $100 $250 $ __________

I'm joining the Coalition at a $50 level or higher so please send me all of your print materials in English. I also would like to receive whatever translations you have in:
Spanish Spanish Spanish Spanish Spanish
Arabic Arabic Arabic Arabic Arabic
Chinese Chinese Chinese Chinese Chinese
Hmong Hmong Hmong Hmong Hmong
Laotian Laotian Laotian Laotian Laotian

Resources for Asians and Pacific Islanders
Send me your Asian and Pacific Islander resource list/order form by: fax mail

Please check enclosed
Method of payment: Check enclosed
Credit card
Visa Mastercard Am. Express
Discover Exp. Date

Card #

Grand Total $ __________

Check enclosed

Needle TIPS • Spring/Summer 1999 (printed 3/99) • 1573 Selby Avenue, St. Paul, MN 55104 • 651/647-9009 • www.immunize.org
Do you want to keep receiving NEEDLE TIPS?

We need your help to clean up our mailing list! Let us know if you want to keep receiving NEEDLE TIPS & the Hepatitis B Coalition News.

Please check the appropriate box or boxes and return a copy of this entire page by:

- FAX: 651-647-9131
- mail (envelope enclosed)

☐ Yes!  I want to keep getting NEEDLE TIPS!
☐ My mailing label is correct.
☐ I've corrected my mailing label.

☐ No

☐ Too many copies!
I've been receiving more than one copy. I'm sending you all labels that I receive and I've marked the address that I want you to use for future mailings.

☐ No one here by that name
The person named on the label below is no longer at this address.

The Coalition has over 2,000 members! How about you?

Thank you for your support!
The Coalition receives tremendous support from our readers. Thank you so much.

Thank you to CDC!
The CDC provides invaluable technical support as well as a federal grant.

Thank you for your educational grants!
• American Pharmaceutical Association
• Aviron
• Chiron Corporation
• Glaxo Wellcome
• Medical Arts Press
• Merck & Co.
• North American Vaccine
• Pasteur Mérieux Connaught
• SmithKline Beecham
• Wyeth-Lederle Vaccines and Pediatrics

Welcome to the National Certification Board of Pediatric Nurse Practitioners and Nurses!
The IAC receives funding from a variety of sources but has strict editorial independence.

We appreciate and need the membership contributions that over 2,000 members have sent us. We hope that more of you will become new or renewing members for 1999. With a contribution of $50 or more, we’ll send you a complete packet of our print materials which includes many new and revised items. Won’t you please join or rejoin today?

☐ Here’s my 1999 membership contribution to the Immunization Action Coalition!

Name/Title: ________________________________________________________
Organization: _______________________________________________________
Address: ___________________________________________________________
City/State/Zip: _______________________________________________________
Phone and E-mail: ____________________________________________________

☐ $50 ☐ $75 ☐ $100 ☐ $250 ☐ $500 ☐ other

☐ I’m joining at a $50 or higher level so please send me your print materials in:
☐ English ☐ Spanish ☐ Armenian ☐ Cambodian ☐ Chinese ☐ Farsi ☐ Hmong ☐ Japanese ☐ Korean
☐ Laotian ☐ Portuguese ☐ Romanian ☐ Russian ☐ Samoan ☐ Somali ☐ Tagalog ☐ Vietnamese

Method of payment:  ☐ Check enclosed ☐ Credit card
Card # ____________________________

Thank you for your support!
The Coalition receives tremendous support from our readers. Thank you so much.

Thank you to CDC!
The CDC provides invaluable technical support as well as a federal grant.

Thank you for your educational grants!
• American Pharmaceutical Association
• Aviron
• Chiron Corporation
• Glaxo Wellcome
• Medical Arts Press
• Merck & Co.
• North American Vaccine
• Pasteur Mérieux Connaught
• SmithKline Beecham
• Wyeth-Lederle Vaccines and Pediatrics

Welcome to the National Certification Board of Pediatric Nurse Practitioners and Nurses!
The IAC receives funding from a variety of sources but has strict editorial independence.

We appreciate and need the membership contributions that over 2,000 members have sent us. We hope that more of you will become new or renewing members for 1999. With a contribution of $50 or more, we’ll send you a complete packet of our print materials which includes many new and revised items. Won’t you please join or rejoin today?

☐ Here’s my 1999 membership contribution to the Immunization Action Coalition!

Name/Title: ________________________________________________________
Organization: _______________________________________________________
Address: ___________________________________________________________
City/State/Zip: _______________________________________________________
Phone and E-mail: ____________________________________________________

☐ $50 ☐ $75 ☐ $100 ☐ $250 ☐ $500 ☐ other

☐ I’m joining at a $50 or higher level so please send me your print materials in:
☐ English ☐ Spanish ☐ Armenian ☐ Cambodian ☐ Chinese ☐ Farsi ☐ Hmong ☐ Japanese ☐ Korean
☐ Laotian ☐ Portuguese ☐ Romanian ☐ Russian ☐ Samoan ☐ Somali ☐ Tagalog ☐ Vietnamese

Method of payment:  ☐ Check enclosed ☐ Credit card
Card # ____________________________

Immunization Action Coalition
NEEDLE TIPS & the Hepatitis B Coalition News
1573 Selby Avenue, Suite 234
Saint Paul, MN 55104

Immunization Action Coalition
NEEDLE TIPS & the Hepatitis B Coalition News
1573 Selby Avenue, Suite 234
Saint Paul, MN 55104